

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076434 A1

(51) International Patent Classification⁷: **C07D 403/04**,
405/14, A61K 31/505

D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number: PCT/GB03/00935

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(22) International Filing Date: 6 March 2003 (06.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0205695.0 9 March 2002 (09.03.2002) GB
0217633.7 31 July 2002 (31.07.2002) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NEWCOMBE, Nicholas, John** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
THOMAS, Andrew, Peter [GB/GB]; AstraZeneca R &

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY



(I)

(57) Abstract: Compounds of the formula (I): wherein R¹, R², R³, R⁴, R⁵ and p are as defined within and a pharmaceutically acceptable salts and *in vivo* hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

WO 03/076434 A1

IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY

The invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cell-proliferation (such as anti-cancer) activity and are therefore useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cell-proliferation effect in a warm-blooded animal such as man.

A family of intracellular proteins called cyclins play a central role in the cell cycle. The synthesis and degradation of cyclins is tightly controlled such that their level of expression fluctuates during the cell cycle. Cyclins bind to cyclin-dependent serine/threonine kinases (CDKs) and this association is essential for CDK (such as CDK1, CDK2, CDK4 and/or CDK6) activity within the cell. Although the precise details of how each of these factors combine to regulate CDK activity is poorly understood, the balance between the two dictates whether or not the cell will progress through the cell cycle.


The recent convergence of oncogene and tumour suppressor gene research has identified regulation of entry into the cell cycle as a key control point of mitogenesis in tumours. Moreover, CDKs appear to be downstream of a number of oncogene signalling pathways. Disregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells.

Accordingly it has been recognised that an inhibitor of cell cycle kinases, particularly inhibitors of CDK2, CDK4 and/or CDK6 (which operate at the S-phase, G1-S and G1-S phase respectively) should be of value as a selective inhibitor of cell proliferation, such as growth of mammalian cancer cells.

The present invention is based on the discovery that certain pyrimidine compounds surprisingly inhibit the effects of cell cycle kinases showing selectivity for CDK2, CDK4 and CDK6, and thus possess anti-cell-proliferation properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma,

acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

Accordingly, the present invention provides a compound of formula (I):



(I)

wherein:

R¹ is halo, cyano, C₁₋₃alkyl or C₁₋₃alkoxy;

p is 0-2; wherein the values of R¹ may be the same or different;

R² is hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, a heterocyclyl or heterocyclylC₁₋₃alkyl; wherein R² may be optionally substituted on carbon by one or more hydroxy, methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R³ is hydrogen, halo or cyano;

R⁴ is C₁₋₆alkyl or C₁₋₆alkoxyC₁₋₆alkyl;

R⁵ is substituted methyl, optionally substituted C₂₋₆alkyl, C₃₋₆cycloalkyl or optionally substituted C₂₋₆alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenyl, methylamino, ethylamino, dimethylamino, diethylamino, methylthio, ethylthio, propylthio, isopropylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl, methylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-

methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

10 According to a further feature of the present invention there is provided a compound of formula (I) (as depicted above) wherein:

R^1 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 0-2; wherein the values of R^1 may be the same or different;

15 R^2 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

20 R^3 is hydrogen, halo or cyano;

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

R^5 is substituted methyl, optionally substituted C_{2-6} alkyl or optionally substituted C_{2-6} alkenyl; wherein said substituents are selected from one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

25 provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-

(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl)anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

According to a further feature of the present invention there is provided a compound of formula (I) (as depicted above) wherein:

R^1 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 0-2; wherein the values of R^1 may be the same or different;

R^2 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl,

2,2,2-trifluoroethyl or methoxyethyl;

R^3 is hydrogen, halo or cyano;

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

R^5 is substituted methyl, optionally substituted C_{2-6} alkyl, C_{3-6} cycloalkyl or optionally substituted C_{2-6} alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl)anilino]pyrimidine;

anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-(4-[N-(2-methoxyethyl)sulphamoyl]anilino)pyrimidine.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₆alkyl", "C₂₋₆alkyl", "C₁₋₄alkyl" and "C₁₋₃alkyl" include propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals, for example "C₃₋₆cycloalkylC₁₋₃alkyl" includes cyclopropylmethyl, 1-cyclobutylethyl and 3-cyclopropylpropyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 4-6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, and a ring sulphur atom may be optionally oxidised to form the S-oxide(s). Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, thienyl, thiadiazolyl, piperazinyl, thiazolidinyl, thiomorpholino, pyrrolinyl, tetrahydropyranyl, tetrahydrofuryl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl and isoxazolyl. Suitably a "heterocyclyl" is tetrahydrofuryl.

Examples of "C₁₋₃alkoxy" include, methoxy, ethoxy and propoxy. Examples of "C₂₋₆alkenyl" and "C₂₋₄alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₄alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "C₃₋₆cycloalkyl" are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of "heterocyclylC₁₋₃alkyl" include pyridylmethyl, 3-morpholinopropyl and 2-pyrimid-2-ylethyl. Examples of "C₁₋₆alkoxyC₁₋₆alkyl" and "C₁₋₄alkoxyC₁₋₄alkyl" are methoxymethyl, 2-methoxyethyl and 2-ethoxypropyl.

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is

sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or

5 tris-(2-hydroxyethyl)amine.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl,

10 C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

15 An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups

20 for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

25 Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess CDK inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK inhibitory activity. In particular the skilled reader will appreciate that

30 when R⁴ is hydrogen, the imidazole ring as drawn in formula (I) may tautomerise.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be

understood that the invention encompasses all such solvated forms which possess CDK inhibitory activity.

Suitable values of R^1 , R^2 , R^3 , R^4 , R^5 and p are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore.

5 R^1 is fluoro, chloro, cyano, methyl, ethyl, methoxy or ethoxy.

p is 0.

p is 1.

p is 2; wherein the values of R^1 may be the same or different.

10 R^2 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, methoxy, ethoxy, trifluoromethyl.

R^2 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more methoxy, ethoxy, trifluoromethyl.

15 R^2 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more hydroxy, methoxy, ethoxy or trifluoromethyl.

20 R^2 is methyl, ethyl, propyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, methoxy, ethoxy, trifluoromethyl.

R^2 is methyl, ethyl, propyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl; wherein R^2 may be optionally substituted on carbon by one or more methoxy, ethoxy, trifluoromethyl.

25 R^2 is hydrogen, methyl, ethyl, propyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl; wherein R^2 may be optionally substituted on carbon by one or more hydroxy, methoxy, ethoxy, trifluoromethyl.

R^2 is 2-ethoxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl.

30 R^2 is hydrogen, 2-ethoxyethyl, 2-methoxyethyl, 2-hydroxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl.

R^3 is hydrogen.

R^4 is C_{1-4} alkyl or C_{1-4} alkoxy C_{1-4} alkyl.

R⁴ is C₁₋₆alkyl.

R⁴ is C₁₋₄alkyl.

R⁴ is methyl, ethyl, isopropyl or 1-methoxyprop-2-yl.

R⁴ is methyl, ethyl, propyl, isopropyl or 1-methoxyprop-2-yl.

5 R⁵ is substituted methyl or optionally substituted C₂₋₆alkyl; wherein said substituents are selected from one or more methoxy.

R⁵ is substituted methyl, C₃₋₆cycloalkyl, optionally substituted C₂₋₆alkenyl or optionally substituted C₂₋₆alkyl; wherein said substituents are selected from one or more methoxy or hydroxy.

10 R⁵ is substituted methyl, optionally substituted C₂₋₆alkyl, C₃₋₆cycloalkyl or optionally substituted C₂₋₆alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, isopropoxy, phenyl, ethylamino, dimethylamino, methylthio, ethylthio, isopropylthio, ethylsulphinyl or ethylsulphonyl.

R⁵ is methoxymethyl, isopropyl, ethyl, butyl or 3,3-dimethylbutyl.

15 R⁵ is methoxymethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, propyl, isopropyl, ethyl, butyl, isobutyl, cyclopropyl, 2-methyl-1-propenyl, 3-butenyl, 1-propenyl or 3,3-dimethylbutyl.

20 R⁵ is methoxymethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, propyl, isopropyl, ethyl, butyl, isobutyl, cyclopropyl, 2-methyl-1-propenyl, 3-butenyl, 1-propenyl, 3,3-dimethylbutyl, phenethyl, dimethylaminomethyl, ethylaminomethyl, ethoxymethyl, methylthiomethyl, isopropylthiomethyl, ethylthiomethyl, ethylsulphinlmethyl, ethylsulphonylmethyl or isopropoxymethyl.

Therefore in another aspect of the invention, there is provided a compound of formula

(I) (as depicted above) wherein:

25 p is 0;

R² is C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl or heterocyclylC₁₋₃alkyl; wherein R² may be optionally substituted on carbon by one or more methoxy, ethoxy, trifluoromethyl;

R³ is hydrogen;

30 R⁴ is C₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

R⁵ is substituted methyl or optionally substituted C₂₋₆alkyl; wherein said substituents are selected from one or more methoxy;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl)anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

Therefore in another aspect of the invention, there is provided a compound of formula

(I) (as depicted above) wherein:

p is 0;

R^2 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more methoxy, ethoxy, trifluoromethyl;

R^3 is hydrogen;

R^4 is C_{1-4} alkyl or C_{1-4} alkoxy C_{1-4} alkyl;

R^5 is substituted methyl, C_{3-6} cycloalkyl, optionally substituted C_{2-6} alkenyl or optionally substituted C_{2-6} alkyl; wherein said substituents are selected from one or more methoxy or hydroxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine;

anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(*N*-cyclobutyl-sulphamoyl)anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-[4-[*N*-(2-methoxyethyl)sulphamoyl]anilino]pyrimidine.

Therefore in another aspect of the invention, there is provided a compound of formula

5 (I) (as depicted above) wherein:

p is 0;

R^2 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more hydroxy, methoxy, ethoxy or trifluoromethyl;

10 R^3 is hydrogen;

R^4 is C_{1-4} alkyl or C_{1-4} alkoxy C_{1-4} alkyl; or

R^5 is substituted methyl, optionally substituted C_{2-6} alkyl, C_{3-6} cycloalkyl or optionally substituted C_{2-6} alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, isopropoxy, phenyl, ethylamino, dimethylamino, methylthio, ethylthio, isopropylthio, ethylsulphinyl or ethylsulphonyl;

15 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-[*N*-(2-methoxyethyl)sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-[4-[*N*-(2-methoxyethyl)sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-[4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-[4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino]pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(*N*-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(*N*-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-[4-[*N*-(2-methoxyethyl)sulphamoyl]anilino]pyrimidine.

20

25

Therefore in an additional aspect of the invention, there is provided a compound of formula (I) (as depicted above) wherein:

30 p is 0;

R^2 is 2-ethoxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl;

R^3 is hydrogen;

R⁴ is methyl, ethyl, isopropyl or 1-methoxyprop-2-yl;

R⁵ is methoxymethyl, isopropyl, ethyl, butyl or 3,3-dimethylbutyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl)anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

Therefore in an additional aspect of the invention, there is provided a compound of formula (I) (as depicted above) wherein:

p is 0;

R² is 2-ethoxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl;

R³ is hydrogen;

R⁴ is methyl, ethyl, propyl, isopropyl or 1-methoxyprop-2-yl;

R⁵ is methoxymethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, propyl, isopropyl, ethyl, butyl, isobutyl, cyclopropyl, 2-methyl-1-propenyl, 3-butenyl, 1-propenyl or 3,3-dimethylbutyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-

(1-methyl-2-trifluoromethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl)anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl)anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

Therefore in an additional aspect of the invention, there is provided a compound of formula (I) (as depicted above) wherein:

p is 0;

R² is hydrogen, 2-ethoxyethyl, 2-methoxyethyl, 2-hydroxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl;

R³ is hydrogen;

R⁴ is methyl, ethyl, propyl, isopropyl or 1-methoxyprop-2-yl; or

R⁵ is methoxymethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, propyl, isopropyl, ethyl, butyl, isobutyl, cyclopropyl, 2-methyl-1-propenyl, 3-butenyl, 1-propenyl, 3,3-dimethylbutyl, phenethyl, dimethylaminomethyl, ethylaminomethyl, ethoxymethyl, methylthiomethyl, isopropylthiomethyl, ethylthiomethyl, ethylsulphinylmethyl, ethylsulphonylmethyl or isopropoxymethyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

In another aspect of the invention, particular compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


In another aspect of the invention, particular compounds of the invention are one of

Examples 4, 12, 30, 31, 44, 51, 54, 58, 60 or 61 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

A particular aspect of the invention is that which relates to the compound of formula (I) or a pharmaceutically acceptable salt thereof.


5 Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein R^1 , R^2 , R^3 , R^4 , R^5 and p are, unless otherwise specified, as defined in formula (I)) comprises of:

Process a) reaction of a pyrimidine of formula (II):




(II)

wherein L is a displaceable group; with an aniline of formula (III):




(III)

15 *Process b*) reacting a compound of formula (IV):



(IV)


with a compound of formula (V):



(V)


wherein T is O or S; R^x may be the same or different and is C_{1-6} alkyl;

Process c) reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with an amine of formula (VII):



(VII)


10 or

Process d) reacting a pyrimidine of formula (VIII)



(VIII)

with a compound of formula (IX):



where Y is a displaceable group;

and thereafter if necessary:

- 5 i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or

- 10 toluene-4-sulphonyloxy group.

X is a displaceable group, suitable values for X are for example, a fluoro or chloro group. Preferably X is fluoro.

Y is a displaceable group, suitable values for Y are for example, a halogeno or sulphonyloxy group, for example a bromo, iodo or trifluoromethanesulphonyloxy group.

- 15 Preferably Y is iodo.


Specific reaction conditions for the above reactions are as follows.

Process a) Pyrimidines of formula (II) and anilines of formula (III) may be reacted together:

- 20 i) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or *N*-methyl pyrrolidine, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or
- ii) under standard Buchwald conditions (for example see *J. Am. Chem. Soc.*, **118**, 7215; *J. Am. Chem. Soc.*, **119**, 8451; *J. Org. Chem.*, **62**, 1568 and 6066) for example in the presence of
- 25 palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-*t*-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and at a temperature in the range of 25 to
- 30 80°C.

Pyrimidines of the formula (II) where L is chloro may be prepared according to

Scheme 1:




Scheme 1

5 Anilines of formula (III) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process b) Compounds of formula (IV) and compounds of formula (V) are reacted together in a suitable solvent such as *N*-methylpyrrolidinone or butanol at a temperature in the range of 100-200°C, preferably in the range of 150-170°C. The reaction is preferably
10 conducted in the presence of a suitable base such as, for example, sodium hydride, sodium methoxide or potassium carbonate.

Compounds of formula (V) may be prepared according to *Scheme 2:*




Scheme 2

Compounds of formula (IV) and (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

- 5 *Process c)* Compounds of formula (VI) and amines of formula (VII) may be reacted together in the presence of an inert solvent such as *N*-methylpyrrolidinone or pyridine, in the presence of a base for example an inorganic base such as caesium carbonate or in the presence of an organic base such as excess (VII) and at a temperature in the range of 25 to 80°C.

Compounds of formula (VI) (wherein X is chloro) may be prepared according to

- 10 *Scheme 3:*



Scheme 3

Compounds of formula (VIa) may be prepared according to *Process a*, *Process b* or *Process d* but wherein compounds (III), (IV) and (IX) are not substituted by R²NHSO₂⁻.

- 15 *Process d)* Compounds of formula (VIII) and amines of formula (IX) may be reacted together under standard Buchwald conditions as described in *Process a*.

The synthesis of compounds of formula (VIII) is described in *Scheme 1*.

Compounds of formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Amines of formula (VI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting

group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the CDK inhibitory activity of the compound. These properties may be assessed, for example, using the procedures set out in WO 02/04429.

Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be

demonstrated at IC₅₀ concentrations or doses in the range 250µM to 1nM in the in vitro assay described in WO 02/04429.

Typical IC₅₀ values for compounds of the invention when tested in the SRB assay described in WO 02/04429 are in the range 1mM to 1nM.

5 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

10 The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

15 The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However
20 the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
25 defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their CDK inhibitory properties. Accordingly the compounds of the present invention are expected to be
30 useful in the treatment of diseases or medical conditions mediated alone or in part by CDK enzymes, i.e. the compounds may be used to produce a CDK inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention

provide a method for treating the proliferation of malignant cells characterised by inhibition of CDK enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of CDKs. Such a compound of the invention is expected to possess a wide range of anti-cancer properties as CDKs have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian cancer. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, prostate and pancreas. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDKs, especially those tumours which are significantly dependent on CDKs for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin. Particularly "cancer" is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

It is further expected that a compound of the present invention will possess activity against other cell-proliferation diseases in a wide range of other disease states including leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore for use as a medicament; and the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.

According to a further feature of the invention, there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in the manufacture of a medicament for use in the treatment of cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, particularly in the treatment of cancers.

According to a further feature of this aspect of the invention there is provided a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.

According to a further feature of this aspect of the invention there is provided a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as defined herein before. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.

According to an additional feature of this aspect of the invention there is provided a method of treating cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as defined herein before.

Particularly there is provided a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in

vivo hydrolysable ester thereof as defined herein before.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal such as man.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancer in a warm-blooded animal such as man.

Preventing cells from entering DNA synthesis by inhibition of essential S-phase initiating activities such as CDK2 initiation may also be useful in protecting normal cells of the body from toxicity of cycle-specific pharmaceutical agents. Inhibition of CDK2 or 4 will prevent progression into the cell cycle in normal cells which could limit the toxicity of cycle-specific pharmaceutical agents which act in S-phase, G2 or mitosis. Such protection may result in the prevention of hair loss normally associated with these agents.

Therefore in a further aspect of the invention there is provided a compound of formula (I) as defined above or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for use as a cell protective agent.

Therefore in a further aspect of the invention there is provided a compound of formula (I) as defined above or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for use in preventing hair loss arising from the treatment of malignant conditions with

pharmaceutical agents.

Examples of pharmaceutical agents for treating malignant conditions that are known to cause hair loss include alkylating agents such as ifosfamide and cyclophosphamide; antimetabolites such as methotrexate, 5-fluorouracil, gemcitabine and cytarabine; vinca
5 alkaloids and analogues such as vincristine, vinblastine, vindesine, vinorelbine; taxanes such as paclitaxel and docetaxel; topoisomerase I inhibitors such as irinotecan and topotecan; cytotoxic antibiotics such as doxorubicin, daunorubicin, mitoxantrone, actinomycin-D and mitomycin; and others such as etoposide and tretinoin.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically
10 acceptable salt or *in vivo* hydrolysable ester thereof, may be administered in association with a one or more of the above pharmaceutical agents. In this instance the compound of formula (I) may be administered by systemic or non systemic means. Particularly the compound of formula (I) may be administered by non-systemic means, for example topical administration.

Therefore in an additional feature of the invention, there is provided a method of
15 preventing hair loss during treatment for one or more malignant conditions with pharmaceutical agents, in a warm-blooded animal, such as man, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

In an additional feature of the invention, there is provided a method of preventing hair
20 loss during treatment for one or more malignant conditions with pharmaceutical agents, in a warm-blooded animal, such as man, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof in simultaneous, sequential or separate administration with an effective amount of said pharmaceutical agent.

According to a further aspect of the invention there is provided a pharmaceutical
25 composition for use in preventing hair loss arising from the treatment of malignant conditions with pharmaceutical agents which comprises a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, and said pharmaceutical agent, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit
30 comprising a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo*

hydrolysable ester thereof, and a pharmaceutical agent for treating malignant conditions that is known to cause hair loss.

According to a further aspect of the present invention there is provided a kit comprising:

- 5 a) a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, in a first unit dosage form;
- b) a pharmaceutical agent for treating malignant conditions that is known to cause hair loss; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

10 According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, in the manufacture of a medicament for the prevention of hair loss during treatment of malignant conditions with pharmaceutical agents.

According to a further aspect of the present invention there is provided a combination
15 treatment for the prevention of hair loss comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a pharmaceutical agent for treatment of malignant conditions to a warm-blooded animal, such
20 as man.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.

25 The CDK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to
30 treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:

- (i) other cell cycle inhibitory agents that work by the same or different mechanisms from those defined hereinbefore;
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, idoxifene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogesterones, 5 antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luproline), inhibitors of testosterone 5 α -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator 10 receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and
- (iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical 15 oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example 20 cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimetabolic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan). According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore 25 and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of 30 inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

Examples

- 5 The invention will now be illustrated by the following non limiting examples in which, unless stated otherwise:
- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
 - (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent
10 was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30mmHg) with a bath temperature of up to 60°C;
 - (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
 - (iv) in general, the course of reactions was followed by TLC and reaction times are given for
15 illustration only;
 - (v) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectral data;
 - (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
 - (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given
20 in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d₆) as solvent unless otherwise indicated; and peak multiplicities are shown as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad;
 - (viii) chemical symbols have their usual meanings; SI units and symbols are used;
25 (ix) solvent ratios are given in volume:volume (v/v) terms; and
 - (x) mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected by electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP); values for m/z
30 are given; generally, only ions which indicate the parent mass are reported; and unless otherwise stated, the mass ion quoted is (MH)⁺;
 - (xi) unless stated otherwise compounds containing an asymmetrically substituted carbon and/or sulphur atom have not been resolved;

(xii) where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those used in the previous example;

(xvi) the following abbreviations have been used:

DMF	dimethylformamide;
EtOAc	ethyl acetate;
ether	diethyl ether;
MeOH	methanol; and
DCM	dichloromethane;

xvii) where an Isolute SCX-2 column is referred to, this means an "ion exchange" extraction cartridge for adsorption of basic compounds, i.e. a polypropylene tube containing a benzenesulphonic acid based strong cation exchange sorbent, used according to the manufacturers instructions obtained from International Sorbent Technologies Limited, Dyffryn Business Park, Hengeod, Mid Glamorgan, UK, CF82 7RJ;

xviii) where an Isolute amine column is referred to, this means an "ion exchange" extraction cartridge for adsorption of acidic compounds, i.e. a polypropylene tube containing a amino silane covalently bonded to a silica particle used according to the manufacturers instructions obtained from International Sorbent Technologies Limited, Dyffryn Business Park, Hengeod, Mid Glamorgan, UK, CF82 7RJ; and

xix) where a Chemelut column is referred to, this means an extraction cartridge for removal of water, i.e. a polypropylene tube containing diatomaceous earth used according to the manufacturers instructions obtained from Varian, Harbor City, California, USA.

Example 1

4-(1-Methyl-2-isopropylimidazol-5-yl)-2-[4-[N-(cyclobutyl)sulphamoyl]anilino]pyrimidine


Chlorosulphonic acid (150µl, 2.16mmol) was added dropwise to solution of 2-anilino-4-(1-methyl-2-isopropylimidazol-5-yl)pyrimidine (Method 71; 158mg, 0.54mmol) in thionyl chloride (3ml) cooled at 0°C and the mixture stirred at 0°C for 10 minutes then heated at 90°C for 90 minutes. The volatiles were removed by evaporation and the residue was dried under high vacuum (<2mmHg) for 1 hour. The resulting solid was placed under nitrogen and a solution of cyclobutylamine (100µl, 1.08mmol) and diethylmethylaniline (1ml, 15mmol) in MeOH (3ml) added. The mixture was stirred for 30 minutes and the volatiles were evaporated in vacuo. Trituration with water results in a solid which was washed water (3 x 20ml)

collected by filtration and dried under vacuum at 60°C to yield the title compound (151mg, 65%) as a solid. NMR: 1.24 (d, 6H), 1.45 (m, 2H), 1.70 (m, 2H), 1.90 (m, 2H), 3.17 (m, 1H), 3.58 (m, 1H), 3.98 (s, 3H), 7.19 (d, 1H), 7.70 (m, 4H), 7.92 (d, 2H), 8.41 (d, 1H), 9.90 (brs, 1H); m/z 427.





5






Examples 2 - 23






The following compounds were prepared by the procedure of Example 1 using the appropriate starting materials.









Ex	R ¹	R ²	R ³	NMR	M/z	SM
2 1,3	Et	Et		1.25 (t, 3H), 1.36 (t, 3H), 1.51 (m, 1H), 1.78 (m, 3H), 2.75 (s, 2H), 3.08 (q, 2H), 3.55 (m, 1H), 3.65 (m, 1H), 3.74 (quin, 1H), 4.76 (q, 2H), 7.39 (d, 1H), 7.55 (br t, 1H), 7.72 (d, 2H), 7.88 (d, 2H), 8.49 (s, 1H), 8.65 (d, 1H), 10.16 (s, 1H)	457	Meth 73
3 1,3	Et	Et		1.25 (t, 3H), 1.36 (t, 3H), 2.87 (s, 2H), 3.08 (q, 2H), 3.16 (s, 3H), 3.29 (t, 2H), 4.76 (q, 2H), 7.40 (d, 1H), 7.55 (brs, 1H), 7.73 (d, 2H), 7.88 (d, 2H), 8.51 (s, 1H), 8.65 (d, 1H), 10.16 (s, 1H)	431	Meth 73

Ex	R ¹	R ²	R ³	NMR	M/z	SM
4 1,3	Et	Et		1.04 (t, 3H), 1.25 (t, 3H), 1.36 (t, 3H), 2.88 (q, 2H), 3.09 (q, 2H), 3.34 (m, 4H), 4.76 (q, 2H), 7.40 (d, 1H), 7.53 (t, 1H), 7.72 (d, 2H), 7.88 (d, 2H), 8.49 (s, 1H), 8.65 (d, 1H), 10.16 (s, 1H)	445	Meth 73
5 1,3	Et	Et		1.26 (t, 3H), 1.37 (t, 3H), 1.59 (quintet, 2H), 2.76 (m, 2H), 3.08 (m, 2H), 3.15 (s, 3H), 3.27 (t, 2H), 4.76 (q, 2H), 7.40 (m, 2H), 7.71 (d, 2H), 7.89 (d, 2H), 8.49 (s, 1H), 8.67 (d, 1H), 10.16 (s, 1H)	445	Meth 73
6 1,4	Et	MeOCH ₂ -		1.30 (t, 3H), 1.55 (m, 1H), 1.77 (m, 2H), 1.87 (m, 1H), 2.79 (m, 2H), 3.45 (s, 3H), 3.60 (m, 1H), 3.71 (m, 1H), 3.83 (m, 1H), 4.77 (q, 2H), 4.87 (s, 2H), 7.42 (d, 1H), 7.57 (t, 1H), 7.78 (d, 2H), 7.90 (d, 2H), 8.45 (s, 1H), 8.67 (d, 1H), 10.12 (s, 1H)	473	Meth 72
7 1,4	Et	MeOCH ₂ -		1.05 (t, 3H), 1.28 (t, 3H), 2.88 (m, 2H), 3.35 (q, 4H), 3.43 (s, 3H), 4.77 (q, 2H), 4.88 (s, 2H), 7.40 (d, 1H), 7.52 (brs, 1H), 7.73 (d, 2H), 7.88 (d, 2H), 8.53 (s, 1H), 8.68 (d, 1H), 10.16 (s, 1H)	461	Meth 72

Ex	R ¹	R ²	R ³	NMR	M/z	SM
8 1,4	Et	MeOCH ₂ -	NH- 	1.27 (t, 3H), 1.59 (quintet, 2H), 2.78 (q, 2H), 3.16 (s, 3H), 3.28 (t, 2H), 3.42 (s, 3H), 4.75 (q, 2H), 4.84 (s, 2H), 7.41 (m, 2H), 7.73 (d, 2H), 7.89 (d, 2H), 8.44 (s, 1H), 8.67 (d, 1H), 10.10 (s, 1H)	461	Meth 72
9 1,4	Et	MeOCH ₂ -	NH- 	1.30 (t, 3H), 2.88 (q, 2H), 3.18 (s, 3H), 3.33 (t, 2H), 3.45 (s, 3H), 4.77 (q, 2H), 4.85 (s, 2H), 7.40 (d, 1H), 7.55 (t, 1H), 7.73 (d, 2H), 7.90 (d, 2H), 8.43 (s, 1H), 8.67 (d, 1H), 10.12 (s, 1H)	447	Meth 72
10 1,2	Me	MeOCH ₂ -	NH- 	0.07 (m, 2H), 0.35 (m, 2H), 0.80 (m, 1H), 2.63 (t, 2H), 3.30 (s, 3H), 4.02 (s, 3H), 4.55 (s, 2H), 7.25 (d, 1H), 7.50 (t, 1H), 7.70 (m, 3H), 7.90 (d, 2H), 8.48 (d, 1H), 9.95 (s, 1H)	429	Meth 70
11 1,4	Me	MeOCH ₂ -	NH- 	1.52 (m, 2H), 1.75 (m, 2H), 1.91 (m, 2H), 3.31 (s, 3H), 3.61 (m, 1H), 4.03 (s, 3H), 4.55 (s, 2H), 7.28 (d, 1H), 7.70 (m, 4H), 7.90 (d, 2H), 8.51 (d, 1H), 9.98 (s, 1H)	429	Meth 70
12	i- Pr	MeOCH ₂ -	NH- 	1.06 (t, 3H), 1.53 (d, 6H), 2.84 (m, 2H), 3.16 (m, 4H), 3.48 (s, 3H), 4.92 (s, 2H), 5.55 (m, 1H), 7.27 (d, 1H), 7.53 (m, 1H), 7.74 (d, 2H), 7.89 (d, 2H), 8.27 (s, 1H), 8.71 (d, 1H), 10.19 (s, 1H)	476	Meth 69

Ex	R ¹	R ²	R ³	NMR	M/z	SM
13 1,6	Me	<i>i</i> -Pr		1.05 (t, 3H), 1.40 (d, 6H), 2.88 (br q, 2H), 3.33 (m, 4H), 3.55 (br s), 4.19 (s, 3H), 7.41 (d, 1H), 7.57 (br t, 1H), 7.76 (d, 2H), 7.94 (d, 2H), 8.50 (s, 1H), 8.70 (d, 1H), 10.29 (s, 1H)	445	Meth 71
14 1,7	Me	<i>i</i> -Pr		1.41 (d, 6H), 3.58 (m, 1H), 3.68 (m, 2H), 4.20 (s, 3H)(not integrated as covered by overlapping exchangeables), 7.42 (d, 1H), 7.80 (d, 2H), 7.99 (d, 2H), 8.48 (t, 1H), 8.49 (s, 1H), 8.70 (d, 1H), 10.30 (s, 1H), 15.00 (v br s, 0.7H)	455	Meth 71
15 1,7	Me	<i>i</i> -Pr		1.11 (s, 9H), 1.41 (d, 6H), 3.59 (m, 1H), 4.18 (s, 3H), 7.35 (s, 1H), 7.41 (d, 1H), 7.78 (d, 2H), 7.91 (d, 2H), 8.49 (s, 1H), 8.70 (d, 1H), 10.22 (s, 1H)	429	Meth 71
16	Me	Et		1.08 (s, 9H), 1.32 (t, 3H), 3.05 (q, 2H), 4.08 (s, 3H), 7.32 (s, 1H), 7.36 (d, 1H), 7.75 (d, 2H), 7.89 (d, 2H), 8.41 (s, 1H), 8.68 (d, 1H), 10.17 (s, 1H)	415	⁵
17	Me	<i>c</i> -Pr		1.08 (t, 3H), 1.27 (m, 4H), 2.40 (m, 1H), 2.89 (m, 2H), 3.35 (m, 4H), 4.21 (s, 3H), 7.37 (d, 1H), 7.50 (m, 1H), 7.73 (d, 2H), 7.93 (d, 2H), 8.40 (s, 1H), 8.65 (d, 1H), 10.24 (s, 1H)	443	Meth 79

Ex	R ¹	R ²	R ³	NMR	M/z	SM
18	Me	c-Pr		1.26 (m, 4H), 2.40 (m, 1H), 2.87 (m, 2H), 3.18 (s, 3H), 3.32 (t, 2H), 4.21 (s, 3H), 7.38 (d, 1H), 7.53 (m, 1H), 7.73 (d, 2H), 7.93 (d, 2H), 8.40 (s, 1H), 8.65 (d, 1H), 10.24 (s, 1H)	429	Meth 79
19	Me	c-Pr		1.26 (m, 4H), 1.65 (m, 4H), 2.40 (m, 1H), 2.78 (m, 2H), 3.55 (m, 1H), 3.70 (m, 1H), 3.88 (m, 1H), 4.21 (s, 3H), 7.38 (d, 1H), 7.53 (m, 1H), 7.73 (d, 2H), 7.93 (d, 2H), 8.40 (s, 1H), 8.67 (d, 1H), 10.24 (s, 1H)	455	Meth 79
20	Me	c-Pr		0.30 (m, 4H), 1.26 (m, 4H), 1.65 (m, 4H), 2.13 (m, 1H), 2.40 (m, 1H), 4.21 (s, 3H), 7.38 (d, 1H), 7.73 (m, 3H), 7.93 (d, 2H), 8.40 (s, 1H), 8.67 (d, 1H), 10.22 (s, 1H)	411	Meth 79
21	n-Pr	c-Pr		0.70 (t, 2H), 1.05 (t, 3H), 1.29 (m, 4H), 1.68 (m, 2H), 2.50 (m, 1H), 2.85 (m, 2H), 3.33 (m, 4H), 4.82 (t, 2H), 7.38 (d, 1H), 7.53 (m, 1H), 7.73 (d, 2H), 7.87 (d, 2H), 8.40 (s, 1H), 8.64 (s, 1H), 10.17 (s, 1H)	471	Meth 80
22	n-Pr	c-Pr		0.70 (t, 2H), 1.32 (m, 4H), 1.68 (m, 2H), 2.50 (m, 1H), 2.85 (m, 2H), 3.17 (s, 3H), 3.33 (t, 2H), 4.82 (t, 2H), 7.38 (d, 1H), 7.53 (m, 1H), 7.73 (d, 2H), 7.87 (d, 2H), 8.41 (s, 1H), 8.64 (s, 1H), 10.17 (s, 1H)	457	Meth 80

Ex	R ¹	R ²	R ³	NMR	M/z	SM
23	n-Pr	c-Pr	NH 	0.30 (m, 4H), 0.70 (t, 2H), 1.32 (m, 4H), 1.68 (m, 2H), 2.05 (m, 1H), 2.50 (m, 1H), 3.17 (s, 3H), 4.83 (t, 2H), 7.38 (d, 1H), 7.74 (m, 3H), 7.87 (d, 2H), 8.41 (s, 1H), 8.64 (s, 1H), 10.17 (s, 1H)	439	Meth 80

¹ Isolated as HCl salt

² Purified by flash silica chromatography DCM:MeOH (Polarity increasing from 100:0 to 97:3)

³ Purified by Isolute amine column

5 ⁴ Purified by Isolute amine column followed by flash silica chromatography DCM:MeOH (Polarity increasing from 100:0 to 97:3)

⁵ Example 29 of WO 02/20512

⁶ Ethyldimethylamine used in place of diethylmethylamine. Work-up:- extracted with EtOAc, washed with dilute NaHCO₃, water and brine

10 ⁷ Ethyldimethylamine used in place of diethylmethylamine. Product purified by flash silica chromatography DCM:MeOH (96:4)


Example 24




4-(1-Methyl-2-isopropylimidazol-5-yl)-2-{4-[N-(cyclopropyl)sulphamoyl]anilino}pyrimidine






15 Chlorosulphonic acid (150μl, 2.16mmol) was added dropwise to solution of 2-anilino-4-(1-methyl-2-isopropylimidazol-5-yl)pyrimidine (Method 71; 158mg, 0.54mmol) in thionyl chloride (3ml) cooled at 0°C and the mixture stirred at 0°C for 10 minutes then heated at 90°C for 90 minutes. The volatiles were removed by evaporation and the residue was dried under high vacuum (<2mmHg) for 1 hour. The resulting solid was placed under nitrogen and a
20 solution of cyclopropylamine (570μl, 8.1mmol) in MeOH (3ml) added. The mixture was stirred for 30 minutes and the volatiles were evaporated in vacuo. Trituration with water results in a solid which was washed water (3 x 20ml) collected by filtration and dried under vacuum at 60°C to yield the title compound (205mg, 92%) as a solid. NMR: 0.30 (m, 2H), 0.45 (m, 2H), 1.24 (d, 6H), 2.19 (m, 1H), 3.17 (m, 1H), 4.01 (s, 3H), 7.19 (d, 1H), 7.70 (d, 2H), 7.92 (d, 2H), 8.02 (m, 1H), 8.50 (d, 1H), 9.90 (brs, 1H); m/z 413.
25





Examples 25-71





The following compounds were prepared by the procedure of Example 24 using the appropriate starting materials.











Ex	R ¹	R ²	R ³	NMR	M/z	SM
25 1,2	<i>i</i> -Pr	MeOCH ₂ -	NH- 	0.02 (m, 2H), 0.38 (m, 2H), 0.75 (m, 1H), 1.52 (d, 6H), 2.66 (m, 2H), 3.43 (s, 3H), 4.88 (d, 2H), 5.52 (m, 1H), 7.28 (d, 1H), 7.53 (m, 1H), 7.68 (d, 2H), 7.83 (d, 2H), 8.23 (s, 1H), 8.68 (d, 1H), 10.16 (brs, 1H)	457	Meth 69
26 1,2	<i>i</i> -Pr	MeOCH ₂ -	NH- 	0.32 (m, 2H), 0.53 (m, 2H), 1.52 (d, 6H), 2.07 (m, 1H), 3.47 (s, 3H), 4.92 (d, 2H), 5.52 (m, 1H), 7.28 (d, 1H), 7.74 (m, 3H), 7.83 (d, 2H), 8.21 (s, 1H), 8.68 (d, 1H), 10.20 (brs, 1H)	443	Meth 69
27 1,2	<i>i</i> -Pr	MeOCH ₂ -	NH- 	1.52 (d, 6H), 2.86 (q, 2H), 3.16 (s, 3H), 3.28 (t, 2H), 3.43 (s, 3H), 4.92 (d, 2H), 5.52 (m, 1H), 7.26 (d, 1H), 7.56 (m, 1H), 7.72 (d, 2H), 7.88 (d, 2H), 8.23 (s, 1H), 8.70 (d, 1H), 10.18 (brs, 1H)	461	Meth 69





Ex	R ¹	R ²	R ³	NMR	M/z	SM
28 1,3	Et	MeOCH ₂ -	NH 	0.38 (m, 2H), 0.49 (m, 2H), 1.32 (t, 3H), 2.15 (brs, 1H), 3.45 (s, 3H), 4.80 (q, 2H), 4.88 (s, 2H), 7.45 (d, 1H), 7.78 (d, 3H), 7.95 (d, 2H), 8.50 (s, 1H), 8.70 (d, 1H), 10.20 (s, 1H)	429	Meth 72
29 1,4	Et	MeOCH ₂ -	NH 	1.10 (s, 9H), 1.27 (t, 3H), 3.43 (s, 3H), 4.78 (q, 2H), 4.86 (s, 2H), 7.33 (s, 1H), 7.40 (d, 1H), 7.76 (d, 2H), 7.86 (d, 2H), 8.49 (s, 1H), 8.69 (d, 1H), 10.11 (s, 1H)	445	Meth 72
30 1,3	Et	Et	NH 	0.35 (m, 2H), 0.48 (m, 2H), 1.25 (t, 3H), 1.39 (t, 3H), 2.09 (s, 1H), 3.08 (q, 2H), 4.78 (q, 2H), 7.40 (d, 1H), 7.75 (d, 3H), 7.92 (d, 2H), 8.49 (s, 1H), 8.67 (d, 1H), 10.16 (s, 1H)	413	Meth 73
31 1,3	Et	Et	NH 	1.25 (t, 3H), 1.36 (t, 3H), 3.08 (q, 2H), 3.40 (m, 2H), 4.76 (q, 2H), 5.00 (m, 1H), 5.12 (m, 1H), 5.67 (m, 1H), 7.40 (d, 1H), 7.64 (br t, 1H), 7.73 (d, 2H), 7.88 (d, 2H), 8.49 (s, 1H), 8.65 (d, 1H), 10.16 (s, 1H)	413	Meth 73
32 1,4	Me	MeOCH ₂ -	NH 	0.37 (m, 2H), 0.48 (m, 2H), 2.12 (brs, 1H), 3.30 (s, 3H), 4.03 (s, 3H), 4.55 (s, 2H), 7.29 (d, 1H), 7.68 (m, 4H), 7.95 (d, 2H), 8.52 (d, 1H), 10.00 (s, 1H)	415	Meth 70





Ex	R ¹	R ²	R ³	NMR	M/z	SM
33 ⁵	Me	<i>t</i> -Bu-(CH ₂) ₂ -		0.98 (s, 9H), 1.60 (m, 2H), 2.78 (m, 2H), 2.89 (q, 2H), 3.18 (s, 3H), 3.30 (m, 2H), 3.99 (s, 3H), 7.20 (d, 1H), 7.44 (t, 1H), 7.63 (s, 1H), 7.70 (d, 2H), 7.93 (d, 2H), 8.43 (d, 1H), 9.90 (s, 1H)	473	Meth 104
34 ⁵	Me	<i>t</i> -Bu-(CH ₂) ₂ -		0.98 (s, 9H), 1.04 (t, 3H), 1.60 (m, 2H), 2.68 (m, 2H), 2.87 (m, 2H), 3.30 (m, 4H), 3.98 (s, 3H), 7.20 (d, 1H), 7.42 (t, 1H), 7.64 (s, 1H), 7.71 (d, 2H), 7.92 (d, 2H), 8.43 (d, 1H), 9.90 (s, 1H)	487	Meth 104
35 ²	Me	<i>n</i> -Bu		0.90 (3H, t), 1.04 (3H, t), 1.38 (2H, m), 1.66 (2H, m), 2.74 (2H, t), 2.88 (2H, q), 3.32 (4H, m), 3.98 (3H, s), 7.18 (1H, d), 7.42 (1H, t), 7.71 (2H, d), 7.92 (2H, d), 8.44 (1H, d), 9.90 (1H, s)	459	Meth 89
36 ²	Me	<i>n</i> -Bu		0.92 (3H, t), 1.39 (2H, m), 1.68 (2H, m), 2.74 (2H, t), 2.88 (2H, q), 3.16 (3H, s), 3.28 (2H, hidden), 3.96 (3H, s), 7.19 (1H, d), 7.46 (1H, t), 7.64 (1H, s), 7.70 (2H, d), 7.92 (2H, d), 8.42 (1H, d), 9.90 (1H, s)	445	Meth 89






Ex	R ¹	R ²	R ³	NMR	M/z	SM
37	i-Pr	i-Pr		1.44 (d, 6H), 1.58 (d, 6H), 2.86 (m, 2H), 3.18 (s, 3H), 3.27 (t, 2H), 3.70 (m, 1H), 5.60 (m, 1H), 7.26 (d, 1H), 7.57 (brs, 1H), 7.73 (d, 2H), 7.92 (d, 2H), 8.28 (s, 1H), 8.72 (d, 1H), 10.21 (brs, 1H)	459	Meth 76
38	Me	Et		1.04 (t, 3H), 1.36 (t, 3H), 2.88 (m, 2H), 3.04 (q, 2H), 3.34 (m, 4H), 4.12 (s, 3H), 7.38 (d, 1H), 7.57 (brs, 1H), 7.74 (d, 2H), 7.92 (d, 2H), 8.42 (s, 1H), 8.68 (d, 1H), 10.23 (brs, 1H)	431	7
39	i-Pr	i-Pr		1.03 (t, 3H), 1.42 (d, 6H), 1.57 (d, 6H), 2.84 (m, 2H), 3.34 (m, 4H), 3.69 (m, 1H), 5.59 (m, 1H), 7.25 (d, 1H), 7.53 (brs, 1H), 7.72 (d, 2H), 7.89 (d, 2H), 8.26 (s, 1H), 8.72 (d, 1H), 10.19 (brs, 1H)	473	Meth 76
40	Et	i-Pr		1.33 (t, 3H), 1.42 (d, 6H), 3.09 (m, 3H), 3.25 (s, 3H), 3.42 (t, 2H), 4.63 (q, 2H), 4.86 (t, 1H), 7.04 (d, 1H), 7.29 (s, 1H), 7.59 (s, 1H), 7.75 (d, 2H), 7.81 (d, 2H), 8.38 (s, 1H)	446	Meth 77





Ex	R ¹	R ²	R ³	NMR	M/z	SM
41	Et	i-Pr		1.02 (t, 3H), 1.13 (t, 3H), 1.42 (d, 6H), 2.83 (m, 2H), 3.33 (m, 4H), 3.58 (m, 1H), 4.81 (q, 2H), 7.41 (d, 1H), 7.59 (brs, 1H), 7.72 (d, 2H), 7.91 (d, 2H), 8.58 (s, 1H), 8.63 (d, 1H)	460	Meth 77
42 ⁶	Et	MeOCH ₂ -		1.30 (t, 3H), 3.41 (s, 3H), 3.66 (quintet, 2H), 4.75 (q, 2H), 4.83 (s, 2H), 7.40 (d, 1H), 7.77 (d, 2H), 7.90 (d, 2H), 8.35 (m, 2H), 8.66 (d, 1H), 10.07 (s, 1H)	471	Meth 72
43 ⁶	Me	MeOCH ₂ -		1.03 (t, 3H), 2.90 (m, 2H), 3.32 (q, 4H), 3.45 (s, 3H), 4.13 (s, 3H), 4.87 (s, 2H), 7.41 (d, 1H), 7.54 (s, 1H), 7.75 (d, 2H), 7.93 (d, 2H), 8.46 (s, 1H), 8.70 (d, 1H), 10.26 (s, 1H)	447	Meth 70
44 ⁶	i-Pr	c-Pr		1.30 (m, 2H), 1.41 (m, 2H), 1.67 (d, 6H), 2.58 (m, 1H), 2.92 (q, 2H), 3.20 (s, 3H), 3.33 (t, 2H), 5.75 (quintet, 1H), 7.31 (d, 1H), 7.60 (t, 1H), 7.79 (d, 2H), 7.91 (d, 2H), 8.20 (s, 1H), 8.73 (d, 1H), 10.23 (s, 1H)	457	Meth 81




Ex	R ¹	R ²	R ³	NMR	M/z	SM
45 ⁶	i-Pr	c-Pr		1.09 (t, 3H), 1.35 (m, 2H), 1.41 (m, 2H), 1.67 (d, 6H), 2.57 (m, 1H), 2.91 (q, 2H), 3.38 (m, 4H), 5.71 (quintet, 1H), 7.30 (d, 1H), 7.58 (t, 1H), 7.76 (d, 2H), 7.90 (d, 2H), 8.20 (s, 1H), 8.72 (d, 1H), 10.21 (s, 1H)	471	Meth 81
46 ⁶	Et	c-Pr		1.06 (t, 3H), 1.30 (m, 7H), 2.48 (m, 1H), 2.89 (q, 2H), 3.34 (m, 4H), 4.88 (q, 2H), 7.39 (d, 1H), 7.53 (t, 1H), 7.74 (d, 2H), 7.90 (d, 2H), 8.40 (s, 1H), 8.66 (d, 1H), 10.12 (s, 1H)	457	Meth 82
47 ⁶	Et	c-Pr		1.25 (m, 4H), 1.35 (t, 3H), 2.45 (m, 1H), 2.89 (q, 2H), 3.17 (s, 3H), 3.30 (t, 2H), 4.88 (q, 2H), 7.40 (d, 1H), 7.55 (t, 1H), 7.75 (d, 2H), 7.90 (d, 2H), 8.41 (s, 1H), 8.67 (d, 1H), 10.12 (s, 1H)	443	Meth 82
48	n-Pr	MeOCH ₂ -		(400MHz) 0.71 (t, 3H), 1.60 (sext, 2H), 2.89 (q, 2H), 3.19 (s, 3H), 3.32 (q, 2H), 3.43 (s, 3H), 4.67 (t, 2H), 4.83 (s, 2H), 7.37 (d, 1H), 7.53 (t, 1H), 7.72 (d, 2H), 7.87 (d, 2H), 8.35 (s, 1H), 8.64 (d, 1H), 10.10 (s, 1H)	461	Meth 75



Ex	R ¹	R ²	R ³	NMR	M/z	SM
49	n-Pr	MeOCH ₂ -		(400MHz) 0.69 (t, 3H), 1.07 (t, 3H), 1.61 (sext, 2H), 2.89 (q, 2H), 3.34 (m, 4H), 3.42 (s, 3H), 4.68 (t, 2H), 4.81 (s, 2H), 7.37 (t, 1H), 7.52 (t, 1H), 7.73 (d, 2H), 7.88 (d, 2H), 8.36 (s, 1H), 8.68 (s, 1H), 10.13 (s, 1H)	475	Meth 75
50 ⁸	Me	n-Pr		0.97 (t, 3H), 1.70 (m, 2H), 2.70 (t, 2H), 2.89 (q, 2H), 3.17 (s, 3H), 3.28 (t, 2H), 3.95 (s, 3H), 7.20 (d, 1H), 7.44 (t, 1H), 7.64 (s, 1H), 7.70 (d, 2H), 7.92 (d, 2H), 8.42 (d, 1H), 9.89 (s, 1H)	431	Meth 91
51 ⁸	Me	n-Pr		0.98 (t, 3H), 1.04 (t, 3H), 1.70 (m, 2H), 2.70 (t, 2H), 2.86 (q, 2H), 3.31 (m, 4H), 3.97 (s, 3H), 7.19 (d, 1H), 7.44 (t, 1H), 7.64 (s, 1H), 7.70 (d, 2H), 7.92 (d, 1H), 8.42 (d, 1H), 9.90 (s, 1H)	445	Meth 91
52 ⁹	Me	MeO(CH ₂) ₂ -		3.05 (t, 2H), 3.15 (q, 2H), 3.29 (s, 3H), 3.38 (s, 3H), 3.44 (t, 2H), 3.84 (t, 2H), 4.0 (s, 3H), 4.92 (t, 1H), 7.02 (d, 1H), 7.41 (br s, 1H), 7.59 (s, 1H), 7.80 (m, 4H), 8.40 (d, 1H)	447	Meth 92

Ex	R ¹	R ²	R ³	NMR	M/z	SM
53 ⁹	Me	MeO(CH ₂) ₂ -		1.15 (t, 3H), 3.05 (t, 2H), 3.14 (q, 2H), 3.38 (s, 3H), 3.44 (m, 4H), 3.84 (t, 2H), 3.98 (s, 3H), 5.01 (t, 1H), 7.04 (d, 1H), 7.50 (br s, 1H), 7.80 (m, 4H), 8.40 (d, 1H)	461	Meth 92
54	Et	<i>n</i> -Pr		0.98 (t, 3H), 1.19 (t, 3H), 1.75 (q, 2H), 2.69 (t, 2H), 2.88 (q, 2H), 3.30 (t, 2H), 4.59 (m, 2H), 7.22 (d, 1H), 7.46 (t, 1H), 7.74 (m, 3H), 7.88 (d, 2H), 8.42 (d, 1H), 9.83 (s, 1H)	445	Meth 93
55	Et	<i>n</i> -Pr		0.98 (t, 3H), 1.06 (t, 3H), 1.19 (t, 3H), 1.74 (m, 2H), 2.70 (t, 2H), 2.88 (q, 2H), 3.36 (m, 4H), 4.59 (m, 2H), 7.22 (d, 1H), 7.44 (t, 1H), 7.70 (m, 3H), 7.88 (d, 2H), 8.42 (d, 1H), 9.82 (s, 1H)	458	Meth 93
56	Et	<i>n</i> -Bu		0.97 (t, 3H), 1.18 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.72 (t, 2H), 2.88 (q, 2H), 3.17 (s, 3H), 3.27 (t, 2H), 4.59 (q, 2H), 7.21 (d, 1H), 7.44 (t, 1H), 7.70 (s, 1H), 7.72 (d, 2H), 8.42 (d, 1H), 9.81 (s, 1H)	458	Meth 94

Ex	R ¹	R ²	R ³	NMR	M/z	SM
57	Et	<i>n</i> -Bu		0.92 (t, 3H), 1.06 (t, 3H), 1.18 (t, 3H), 1.38 (m, 2H), 1.69 (m, 2H), 2.74 (t, 2H), 2.88 (q, 2H), 3.37 (m, 2H), 4.58 (q, 2H), 7.20 (d, 1H), 7.43 (t, 1H), 7.68 (s, 1H), 7.70 (d, 2H), 7.84 (d, 2H), 8.42 (d, 1H), 9.82 (s, 1H)	473	Meth 94
58 ⁸	<i>i</i> -Pr	<i>n</i> -Pr		1.0 (t, 1H), 1.48 (d, 6H), 1.79 (m, 2H), 2.78 (t, 2H), 2.86 (m, 2H), 3.30 (t, 2H), 5.59 (m, 1H), 7.15 (d, 1H), 7.45 (m, 2H), 7.78 (d, 2H), 7.88 (d, 2H), 8.44 (d, 1H), 9.86 (s, 1H)	459	Meth 95
59 ⁸	<i>i</i> -Pr	<i>n</i> -Pr		1.0 (m, 6H), 1.48 (d, 6H), 1.78 (m, 2H), 2.77 (t, 2H), 2.85 (q, 2H), 3.32 (m, 4H), 5.58 (m, 1H), 7.16 (d, 1H), 7.44 (m, 2H), 7.69 (d, 2H), 7.88 (d, 2H), 8.45 (d, 1H), 9.85 (s, 1H)	473	Meth 95
60 ⁸	<i>i</i> -Pr	Et		1.28 (t, 3H), 2.48 (d, 6H), 2.86 (m, 4H), 3.29 (t, 2H), 5.59 (m, 1H), 7.15 (d, 1H), 7.44 (m, 2H), 7.70 (d, 2H), 7.86 (d, 2H), 8.45 (d, 1H), 9.84 (s, 1H)	445	Meth 96
61 ⁸	<i>i</i> -Pr	Et		1.04 (t, 3H), 1.28 (t, 3H), 1.46 (d, 6H), 2.82 (m, 4H), 3.35 (m, 4H), 5.59 (m, 1H), 7.15 (d, 1H), 7.24 (m, 2H), 7.69 (d, 2H), 7.86 (d, 2H), 8.43 (d, 1H), 9.85 (s, 1H)	459	Meth 96

Ex	R ¹	R ²	R ³	NMR	M/z	SM
62	<i>i</i> -Pr	EtOCH ₂ -		1.20 (t, 3H), 1.52 (d, 6H), 2.86 (m, 2H), 3.15 (s, 3H), 3.29 (t, 2H), 3.63 (m, 2H), 4.92 (s, 2H), 5.52 (m, 1H), 7.27 (d, 1H), 7.53 (t, 1H), 7.71 (d, 2H), 7.87 (d, 2H), 8.22 (s, 1H), 8.70 (d, 1H), 10.16 (s, 1H)	475	Meth 78
63	Me	<i>i</i> -PrCH ₂ -		0.96 (d, 6H), 2.15-2.08 (m, 1H), 2.61 (d, 2H), 2.88 (q, 2H), 3.18 (s, 3H), 3.30-3.25 (m, 2H), 3.98 (s, 3H), 7.20 (d, 1H), 7.44 (t, 1H), 7.64 (s, 1H), 7.72 (d, 2H), 7.92 (d, 2H), 8.42 (d, 1H), 9.90 (s, 1H)	445	Meth 109
64	Me	<i>i</i> -PrCH ₂ -		0.95 (d, 6H), 1.03 (t, 3H), 2.15-2.07 (m, 1H), 2.30 (d, 2H), 2.88 (q, 2H), 3.18 (d, 2H), 3.38-3.30 (m, 2H), 3.98 (s, 3H), 7.20 (d, 1H), 7.43 (t, 1H), 7.73-7.64 (m, 3H), 7.90 (d, 2H), 8.42 (d, 1H), 9.90 (s, 1H)	459	Meth 109
65	<i>n</i> -Pr	<i>n</i> -Pr		0.62 (t, 3H), 1.0 (t, 3H), 1.51 (q, 2H), 1.75 (q, 2H), 2.70 (t, 2H), 2.89 (q, 2H), 3.18 (s, 3H), 3.30-3.25 (m, 2H), 4.52 (t, 2H), 7.20 (d, 1H), 7.48 (t, 1H), 7.74-7.65 (m, 3H), 7.88 (d, 2H), 8.42 (d, 1H), 9.82 (s, 1H)	459	Meth 99

Ex	R ¹	R ²	R ³	NMR	M/z	SM
66	n-Pr	n-Pr		0.68 (t, 3H), 0.99 (t, 3H), 1.04 (t, 3H), 1.50 (q, 2H), 1.6 (q, 2H), 2.70 (t, 2H), 2.92-2.85 (m, 2H), 3.39-3.28 (m, 2H), 4.51 (t, 2H), 7.20 (d, 2H), 7.43 (t, 1H), 7.68 (s, 1H), 7.70 (d, 2H), 7.88 (d, 2H), 8.42 (d, 1H), 9.82 (s, 1H)	473	Meth 99
67	n-Pr	<i>t</i> -Bu(CH ₂) ₂ -		0.70 (t, 3H), 0.98 (s, 9H), 1.46-1.64 (m, 4H), 2.62-2.72 (m, 2H), 2.87 (q, 2H), 3.18 (s, 3H), 3.27-3.30 (m, 2H), 4.53 (t, 2H), 7.20 (d, 1H), 7.48 (t, 1H), 7.63 (s, 1H), 7.71 (d, 2H), 7.87 (d, 2H), 8.42 (s, 1H), 9.82 (s, 1H)	501	Meth 115
68	Et	n-Pr		0.96 (t, 3H), 1.17 (t, 3H), 1.73 (m, 2H), 2.69 (t, 2H), 2.77 (q, 2H), 3.35 (q, 2H), 4.59 (m, 3H), 7.21 (d, 1H), 7.34 (t, 1H), 7.69 (m, 3H), 7.89 (d, 2H), 8.41 (d, 1H), 9.81 (s, 1H)	431	Meth 93
69	Et	n-Pr	NH ₂	0.98 (t, 3H), 1.25 (t, 3H), 1.80 (m, 2H), 3.06 (t, 2H), 4.78 (q, 2H), 7.09 (br s, 4H), 7.39 (d, 1H), 7.75 (d, 2H), 7.86 (d, 2H), 8.51 (s, 1H), 8.64 (d, 1H), 10.14 (s, 1H)	387	Meth 93

Ex	R ¹	R ²	R ³	NMR	M/z	SM
70 ¹⁰	n-Pr	Me ₂ NCH ₂ -		0.68 (t, 3H), 1.54 (q, 2H), 2.18 (s, 6H), 2.89 (q, 2H), 3.17 (s, 3H), 3.30 (m, 2H), 3.53 (s, 2H), 4.59 (t, 2H), 7.22 (d, 1H), 7.43 (t, 1H), 7.66 (s, 1H), 7.77 (d, 2H), 7.84 (d, 2H), 8.44 (d, 1H), 9.84 (s, 1H)	474	Meth 119
71 ¹⁰	n-Pr	EtNHCH ₂ -		0.68 (t, 3H), 1.05 (t, 3H), 1.51 (m, 2H), 2.57 (m, 2H), 2.88 (m, 2H), 3.18 (s, 3H), 3.28 (m, 2H), 3.80 (s, 2H), 4.59 (t, 2H), 7.20 (d, 1H), 7.50 (s, 1H), 7.68 (s, 1H), 7.70 (d, 2H), 7.88 (d, 2H), 8.43 (d, 1H), 9.85 (s, 1H)	474	Meth 120

¹ Isolated as HCl salt

² Purified by flash silica chromatography DCM:MeOH (Polarity increasing from 100:0 to 97:3)

³ Purified by Isolute amine column

5 ⁴ Purified by Isolute amine column followed by flash silica chromatography DCM:MeOH (Polarity increasing from 100:0 to 97:3)

⁵ Purified by flash silica chromatography DCM:MeOH (95:5)

⁶ Purified by Isolute amine column followed by flash silica chromatography DCM:MeOH (Polarity increasing from 100:0 to 97:3) and isolated as the HCl salt

10 ⁷ Example 29 of WO 02/20512

⁸ Purified by flash silica chromatography DCM:MeOH (98:2)

⁹ Purified by flash silica chromatography DCM:MeOH (98.5:1.5)

¹⁰ Purified by chromatography on silica gel eluting with DCM:MeOH (90:10)


Example 72



4-[1-(Methoxypropyl-2-yl)-2-(methoxymethyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine

To a stirred solution of 2-amino-4-(1-methoxyisopropyl-2-methoxymethylimidazol-5-yl)pyrimidine (Method 85; 163mg, 0.6mmol), *N*-(2-ethoxyethyl)-4-iodobenzenesulphonamide (Method 1; 400mg, 1.2 mmol), tris(dibenzylideneacetone) dipalladium (0) (35mg, 0.038mmol) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (47mg, 0.076mmol) in dioxane (10ml) was added sodium *t*-butoxide (258mg, 2.69mmol) and the mixture heated at 80°C overnight. The reaction was cooled to room temperature and MeOH (5ml) was added and the mixture poured onto an Isolute SCX-2 column, eluted first with MeOH (10 x 30ml) and the product was then eluted with 5% methanolic ammonia (10 x 30ml). The solvent was removed by evaporation and the residue purified by flash chromatography on silica gel eluting with DCM/MeOH (100:0 increasing in polarity to 97:3) to yield a foam which was dissolved in MeOH (2ml) and treated with 1N HCl in ether (350µl, 0.35mmol) for 5 minutes. Solvent was evaporated in vacuo to yield a yellow foam which was triturated with ether to yield after filtration the title compound as a yellow solid (63mg, 20%) NMR: 1.02 (t, 3H), 1.54 (d, 3H), 2.87 (m, 2H), 3.14 (s, 3H), 3.30 (m, 4H), 3.43 (s, 3H), 3.55 (m, 1H), 3.75 (m, 1H), 4.90 (s, 2H), 5.65 (m, 1H), 7.26 (d, 1H), 7.54 (m, 1H), 7.71 (d, 2H), 7.88 (d, 2H), 8.26 (s, 1H), 8.70 (d, 1H), 10.20 (brs, 1H); m/z 505.

Examples 73-74

The following compounds were prepared by the procedure of Example 72 using the appropriate starting materials.



Ex	R ¹	NMR	M/z	SM
73		1.37 (t, 3H), 3.06 (q, 2H), 3.62 (m, 2H), 4.12 (s, 3H), 7.39 (d, 1H), 7.77 (d, 1H), 7.94 (d, 1H), 8.42 (s, 1H), 8.44 (t, 1H), 8.65 (d, 1H), 10.28 (brs, 1H)	441	Meth 86 Meth 2
74		1.35 (t, 3H), 1.58 (m, 2H), 2.76 (m, 2H), 3.04 (q, 2H), 3.17 (s, 3H), 3.24 (t, 2H), 4.10 (s, 3H), 7.37 (d, 1H), 7.39 (t, 1H), 7.71 (d, 1H), 7.92 (d, 1H), 8.39 (s, 1H), 8.66 (d, 1H), 10.21 (brs, 1H)	431	Meth 86 Meth 3

Example 75

2-{4-[N-(2-Methoxyethyl)sulphamoyl]anilino}-4-[1-methyl-2-(2-methyl-2-

5 hydroxypropyl)]imidazol-5-yl]pyrimidine

The title compound was prepared by the procedure of Method 89 using Example 35 of WO 02/20512 and acetone as the starting materials. NMR: 1.20 (s, 6H), 2.88-2.83 (m, 4H), 3.18-3.15 (m, 5H), 4.0 (s, 3H), 4.78 (s, 1H), 7.20 (d, 1H), 7.44 (t, 1H), 7.70-7.67 (m, 3H), 7.90 (d, 2H), 8.46 (d, 1H), 9.90 (s, 1H); m/z 461.

10

Example 76

4-[2-(Prop-1-enyl)-1-(isopropyl)imidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine

n-Butyl lithium (656 µl of a 1.6 N solution in hexane, 1.05mmol), was added dropwise to a solution of ethyl triphenylphosphonium iodide (437mg, 1.05mmol), in anhydrous THF (15ml), under nitrogen at 0°C. A solution of 4-(2-formyl-1-isopropylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxymethyl)sulphamoyl]anilino}pyrimidine (Method 105; 300 mg, 0.523mmol), in THF (5ml), was then slowly added. The mixture was allowed to warm to ambient temperature and stirred for 18 hours. The volatiles were removed by evaporation and the residue dissolved in EtOAc (40ml), washed with water (2 x 15ml), brine (15ml), and dried. The solvent removed by evaporation to give a crude product (254 mg), as a yellow foam. The crude product was purified by chromatography on silica-gel eluting with 3% MeOH in DCM), the semi-pure product (70 mg), was dissolved in TFA/H₂O (1:1, 10ml), and stirred for 1 hour. The TFA was removed by evaporation, the resulting aqueous solution

neutralised with saturated NaHCO_3 , and the product extracted with DCM (3 x 5ml). The extracts were combined, dried and the solvent removed. The residue was purified by preparative reverse phase HPLC, eluting with acetonitrile/ H_2O , 0.01% formic buffer. Pure fractions were neutralised with 2N aqueous sodium hydroxide solution. The resulting white precipitate, was collected by filtration and dried to give the title compound (1: 2.5 mixture of E:Z isomers), as a white solid (5 mg, 2%). NMR: Z isomer 1.51 (d, 6H), 2.09 (d, 3H), 2.92 (t, 2H), 3.17 (s, 3H), 3.33 (t, 2H), 5.60 (m, 1H), 6.05 (m, 1H), 6.51 (m, 1H), 7.1 (br s, 1H), 7.16 (d, 1H), 7.57 (s, 1H), 7.71 (d, 2H), 7.88 (d, 2H), 8.48 (d, 1H), 9.47 (s, 1H); E isomer 1.51 (d, 6H), 1.94 (d, 3H), 2.92 (t, 2H), 3.17 (s, 3H), 3.33 (t, 2H), 5.60 (m, 1H), 6.60 (m, 1H), 6.67 (m, 1H), 7.1 (br s, 1H), 7.13 (d, 1H), 7.47 (s, 1H), 7.71 (d, 2H), 7.88 (d, 2H), 8.44 (d, 1H), 9.47 (s, 1H); m/z: 457.

Example 77

4-[2-(2-Methylprop-1-enyl)-1-ethylimidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine

Aqueous TFA (90%) was added to a mixture of 4-[2-(2-methylprop-1-enyl)-1-ethylimidazol-5-yl]-2-{4-[N-(2-methoxyethyl)-N-t-butylsulphamoyl]anilino}pyrimidine (Method 111; 70mg, 0.14mmol), and anisole (90 μl , 0.83mmol), and the mixture stirred at ambient temperature for 1 hour. The volatiles were evaporated and the residue dissolved in water. The solution was neutralised (NaHCO_3), and extracted with EtOAc. The extracts were dried, and the solvent evaporated to give the title compound (30mg, 41%). NMR: 1.19 (t, 3H), 1.99 (s, 3H), 2.15 (s, 3H), 2.89 (q, 2H), 3.18 (s, 3H), 3.30-3.28 (m, 2H), 4.65 (q, 2H), 6.28 (s, 1H), 7.25 (d, 1H), 7.50 (t, 1H), 7.70 (d, 2H), 7.85 (s, 1H), 7.89 (d, 2H), 8.45 (d, 1H), 9.85 (s, 1H); m/z: 457.

Example 78

4-[2-(2-Methylprop-1-enyl)-1-methylimidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine

2-{4-[N-(2-Methoxyethyl)sulphamoyl]anilino}-4-[1-methyl-2-(2-methyl-2-hydroxypropyl)imidazol-5-yl]pyrimidine (Example 75), was treated by the procedure described in Method 110 to give the title compound (30mg, 14%). NMR: 1.99 (s, 3H), 2.15 (s,

3H), 2.87 (q, 2H), 3.18 (s, 3H), 3.23-3.30 (m, 2H), 4.0 (s, 3H), 6.26 (s, 1H), 7.22 (d, 1H), 7.43 (t, 1H), 7.70 (d, 2H), 7.79 (s, 1H), 7.92 (d, 2H), 8.44 (d, 1H), 9.90 (s, 1H); m/z: 443.

Example 79

5 4-[2-(But-3-en-1-yl)-1-propylimidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine

A mixture of caesium fluoride (180mg, 1.2mmole), and 4-(2-(but-3-enyl)-1-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxymethyl)sulphamoyl]anilino}pyrimidine (Method 100; 100mg, 0.17mmol), in DMF (3ml), was heated at 140°C
10 under nitrogen for 24 hours. The mixture was diluted with water and extracted with EtOAc. The extracts were washed with water and brine, dried, and the solvent evaporated. The residue was purified by chromatography on silica gel eluting with EtOAc to give the title compound.
(8mg, 10%). NMR: 0.7 (t, 3H), 1.52 (q, 2H), 2.80 (t, 2H), 2.85-2.89 (m, 2H), 3.19 (s, 3H),
3.18-3.22 (m, 2H), 3.30 (t, 2H), 4.52 (t, 2H), 4.98 (d, 1H), 5.10 (dd, 1H), 5.95-5.89 (m, 1H),
15 7.20 (d, 1H), 7.44 (t, 1H), 7.70 (s, 3H), 7.74 (d, 2H), 7.89 (d, 2H), 8.45 (d, 1H), 9.80 (s, 1H);
m/z: 471.

Example 80

20 4-[2-(Methylthiomethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine

Sodium thiomethoxide (21mg, 0.3mmol) was added to a stirred solution of 4-[2-(chloromethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine (Method 116; 52mg, 0.1mmol) in MeOH (5ml) and the solution was stirred at ambient temperature for 3 hour. The solvent was removed by evaporation and the residue was
25 partitioned between water and EtOAc. The organic phase was washed with saturated aqueous sodium hydrogen carbonate solution and brine, dried (Na₂SO₄) and the volatiles removed by evaporation. The residue was triturated with ether and collected by filtration. This solid was suspended in MeOH (2ml) and 1.0M ethereal hydrogen chloride was added to give a clear solution. The volatiles were removed by evaporation and the residue triturated with ether
30 giving the title compound (42mg, 80%) as the hydrochloride salt. NMR: 0.72 (t, 3H), 1.06 (t, 3H), 1.63 (m, 2H), 2.18 (s, 3H), 2.88 (q, 2H), 3.35 (m, 4H), 4.42 (s, 2H), 4.72 (m, 2H), 7.37 (d, 1H), 7.54 (t, 1H), 7.75 (d, 2H), 7.89 (d, 2H), 8.39 (s, 1H), 8.68 (d, 1H), 10.14 (s, 1H); m/z 491.

Examples 81-82

The following compounds were prepared by the procedure of Example 80 using 4-[2-(chloromethyl)-1-(propyl)imidazol-5-yl]-2-[4-[N-(2-ethoxyethyl)sulphamoyl]anilino]pyrimidine (Method 116) and the appropriate reagent but without conversion of the free base product to hydrochloride salt.

Ex	Compound	NMR	M/z [MH] ⁺
81	4-[2-(Isopropylthiomethyl)-1-(propyl)imidazol-5-yl]-2-[4-[N-(2-ethoxyethyl)sulphamoyl]anilino]pyrimidine	0.67 (t, 3H), 1.03 (t, 3H), 1.20 (d, 6H), 1.55 (m, 2H), 2.85 (m, 2H), 2.93 (m, 1H), 3.33 (m, 4H), 3.94 (s, 2H), 4.55 (t, 2H), 7.21 (d, 1H), 7.45 (t, 1H), 7.68 (s, 1H), 7.72 (d, 2H), 7.84 (d, 2H), 8.45 (d, 1H), 9.85 (s, 1H)	519
82	4-[2-(Ethylthiomethyl)-1-(propyl)imidazol-5-yl]-2-[4-[N-(2-ethoxyethyl)sulphamoyl]anilino]pyrimidine	0.68 (t, 3H), 1.04 (t, 3H), 1.17 (t, 3H), 1.55 (m, 2H), 2.53 (m, 2H), 2.86 (q, 2H), 3.33 (m, 4H), 3.90 (s, 2H), 4.55 (t, 2H), 7.21 (d, 1H), 7.45 (t, 1H), 7.68 (s, 1H), 7.72 (d, 2H), 7.84 (d, 2H), 8.45 (d, 1H), 9.85 (s, 1H)	505

Example 83

4-[2-(Ethylsulphinylmethyl)-1-(propyl)imidazol-5-yl]-2-[4-[N-(2-ethoxyethyl)sulphamoyl]anilino]pyrimidine

A solution of sodium periodate (43mg, 0.2mmol) in water (0.5ml) was added to a stirred solution of 4-[2-(ethylthiomethyl)-1-(propyl)imidazol-5-yl]-2-[4-[N-(2-ethoxyethyl)sulphamoyl]anilino]pyrimidine (Example 82; 70mg, 0.14mmol) in MeOH (2ml) and the solution was stirred for 18 hours. The MeOH was removed by evaporation and the aqueous residue was extracted with EtOAc. The extracts were combined, washed with brine, dried and the volatiles removed by evaporation. The residue was purified by chromatography on silica gel eluting with DCM / MeOH (95:5 increasing in polarity to 90:10) and the purified product triturated with ether to give the title compound (37mg, 51%). NMR: 0.68 (t, 3H), 1.05 (t, 3H), 1.22 (t, 3H), 1.52 (m, 2H), 2.85 (m, 4H), 3.33 (m, 4H), 4.31 (d of d, 2H), 4.63 (m,

2H), 7.23 (d, 1H), 7.46 (t, 1H), 7.70 (d, 2H), 7.78 (s, 1H), 7.86 (d, 2H), 8.48 (d, 1H), 9.90 (s, 1H); m/z 521.

Example 84

5 4-[2-(Ethylsulphonylmethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]
anilino}pyrimidine

Oxone (123mg, 0.2mmol) was added to a stirred solution of 4-[2-(ethylthiomethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl] anilino}pyrimidine (Example 82; 70mg, 0.14mmol) in MeOH / acetone / water (15:5:3) (2ml) at 0-4°C. The solution was
10 allowed to warm to ambient temperature and stirred for 2hr. The reaction mixture was diluted with water and extracted with EtOAc. The extracts were combined, washed with brine, dried (Na₂SO₄) and the volatiles removed by evaporation. The residue was purified by chromatography on silica gel eluting with DCM / MeOH (95:5) and the purified product
15 triturated with ether to give the title compound (44mg, 59%). NMR: 0.65 (t, 3H), 1.03 (t, 3H), 1.27 (t, 3H), 1.52 (m, 2H), 2.85 (q, 2H), 3.30 (m, 6H), 4.64 (t, 2H), 4.81 (s, 2H), 7.25 (d, 1H), 7.46 (t, 1H), 7.70 (d, 2H), 7.79 (s, 1H), 7.97 (d, 2H), 8.50 (d, 1H), 9.91 (s, 1H); m/z 537.

Example 85

20 4-[2-(Isopropoxymethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]
anilino}pyrimidine

Sodium isopropoxide (87mg, 1.05mmol) was added to a stirred suspension of 4-[2-(chloromethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine (Method 116; 100mg, 0.21 mmol) in isopropanol (20ml). The reaction was stirred for 48 hours at ambient temperature, and was then poured into water (80ml) and extracted
25 with EtOAc (3 x 30ml). The extracts were combined washed with brine (2 x 40ml), dried and the volatiles removed by evaporation. The residue was purified by reverse phase HPLC (C18 column) eluting with aqueous ammonia / water / acetonitrile (5:90:5 decreasing in polarity to (5:0:95) to give the title compound (18mg, 17%) as a brown gum. M/z 503.

Example 86

4-[2-(Phenethyl)-1-(methyl)imidazol-5-yl]-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine

4-{2-[2-(4-Chlorophenyl)ethyl]-1-(methyl)imidazol-5-yl}-2-{4-[N-(2-methoxyethyl)sulphamoyl] anilino}pyrimidine (Method 117; 115mg, 0.219mmol) and triethylamine (34µl, 0.241mmol) was dissolved in ethanol (20ml) and EtOAc (10ml) and 30% palladium on charcoal catalyst (30mg) added. The mixture was stirred for 3 days under an atmosphere of hydrogen. The catalyst was removed by filtration and filtrate evaporated. The residue was dissolved in DCM (20ml), washed with water (2 x 15ml), dried and the solvent removed by evaporation to give the title compound (67mg, 63%) as a white solid. NMR: 2.88 (q, 2H) 3.05 (s, 4H) 3.16 (s, 3H) 3.28 (t, 3H) 3.90 (s, 3H) 7.21 (d, 1H) 7.28 (m, 5H) 7.69 (s, 1H) 7.70 (d, 2H) 8.44 (d, 1H) 9.94 (s, 1H); m/z 493.

Preparation of Starting Materials

The starting materials for the examples above are either commercially available or are readily prepared by standard methods from known materials. For example, the following reactions are an illustration, but not a limitation, of some of the starting materials used in the above reactions.

Method 1

N-(2-Ethoxyethyl)-4-iodobenzenesulphonamide

2-Ethoxyethylamine (2.14g, 24mmol) and diisopropylethylamine (4.2ml, 24mmol) were dissolved in DCM (50ml) and cooled to 0°C. To this was added pipsyl chloride (6.05g, 20mmol) in portions and the reaction stirred for 18 hours. Volatiles were evaporated in vacuo. The residue was dissolved in EtOAc (50ml), extracted 1N citric acid (2 x 50ml), brine (50ml), dried and evaporated in vacuo to yield an oil which solidified on standing to give the title compound as a pale yellow solid (6.97g, 98%). NMR: 1.01 (t, 3H), 2.89 (q, 2H), 3.30 (m, 4H), 7.53 (d, 2H), 7.75 (t, 1H), 7.97 (d, 2H); m/z 354 (M-H)⁺.

Methods 2-5

The following compounds were prepared by the procedure of Method 1 using the appropriate starting materials.

Meth	Compound	NMR	M/z
2	N-(2,2,2-trifluoroethyl)-4-iodosulphonamide	3.69 (q, 2H), 7.58 (d, 2H), 7.93 (d, 2H), 8.65 (brs, 1H)	364 (M-H) ⁻
3	N-(3-Methoxypropyl)-4-iodobenzenesulphonamide	1.68 (m, 2H), 3.02 (q, 2H), 3.21 (s, 3H), 3.38 (t, 2H), 5.10 (s, 1H), 7.51 (d, 2H), 7.80 (d, 2H)	356
4	N-(2-Methoxyethyl)-4-iodobenzenesulphonamide	3.14 (q, 2H), 3.25 (s, 3H), 3.40 (q, 2H), 4.97 (s, 1H), 7.58 (d, 2H), 7.90 (d, 2H)	342
5	N-t-Butyl-4-iodobenzenesulphonamide	1.08 (s, 9H), 7.56 (m, 3H), 7.94 (d, 2H)	338 [MH] ⁺

5 **Methods 6-7**

The following compounds were synthesised by the procedure as described in JOC 1987, 2714-2716.

Meth	Compound
6	5-Methyl-4-(methylamino)isoxazole hydrochloride
7	5-Acetyl-1-methyl-2-(methoxymethyl)imidazole

Methods 8-49

10 The following compounds were prepared using procedures analogous to those described in JOC 1987, 2714-2726.

Meth	Compound	NMR	M/z	SM
8	5-Methyl-4-(N-methyl-N-propionylamino)isoxazole	1.09 (t, 3H), 2.08 (q, 2H), 2.38 (s, 3H), 3.16 (s, 3H), 8.16 (s, 1H)	169	Meth 6
9	1-Methyl-2-ethyl-5-acetylimidazole	1.36 (t, 3H), 2.41 (s, 3H), 2.72 (q, 2H), 3.82 (s, 3H), 7.72 (s, 1H)	153	Meth 8

Meth	Compound	NMR	M/z	SM
10	4-(Isopropylamino)-5-methylisoxazole	(CDCl ₃) 1.12 (d, 6H), 2.30 (s, 3H), 3.21 (1H, sept), 8.01 (s, 1H)	141	4-Amino-5-methylisoxazole hydrochloride
11	5-Methyl-4-(N-isopropyl-N-methoxyacetamido)isoxazole	0.95 (d, 6H), 2.35 (s, 3H), 3.20 (s, 3H), 3.60 (s, 2H), 4.70 (m, 1H), 8.60 (s, 1H)	213	Meth 10
12	1-isopropyl-2-methoxymethyl-5-acetylimidazole	1.43 (d, 6H), 2.40 (s, 3H), 3.24 (s, 3H), 4.50 (s, 2H), 4.90 (m, 1H), 7.92 (s, 1H)	197	Meth 11
13	5-Methyl-4-(N-methyl-N-isobutrylamino)isoxazole	1.03 (d, 6H), 2.36 (s, 3H), 2.48 (m, 1H), 3.16 (s, 3H), 8.20 (s, 1H)	183	Meth 6
14	1-Methyl-2-isopropyl-5-acetylimidazole	1.36 (d, 6H), 2.42 (s, 3H), 3.10 (m, 1H), 3.84 (s, 3H), 7.75 (s, 1H)	167	Meth 13
15	5-Methyl-4-(N-acetamido)isoxazole	2.00 (s, 3H), 2.34 (s, 3H), 8.64 (s, 1H), 9.60 (brs, 1H)	141	4-Amino-5-methylisoxazole hydrochloride
16	5-Methyl-4-(ethylamino)isoxazole hydrochloride	1.21 (t, 3H), 2.58 (s, 3H), 3.22 (q, 2H), 8.76 (s, 1H)	127	Meth 15
17	5-Methyl-4-(N-ethyl-N-methoxyacetamido)isoxazole	(CDCl ₃) 1.12 (t, 3H), 2.39 (s, 3H), 3.36 (s, 3H), 3.64 (q, 2H), 3.75 (s, 2H), 8.16 (s, 1H)	199	Meth 16
18	5-Acetyl-1-ethyl-2-methoxymethylimidazole	(CDCl ₃) 1.37 (t, 3H), 2.48 (s, 3H), 3.38 (s, 3H), 4.39 (q, 2H), 4.56 (s, 2H), 7.74 (s, 1H)	183	Meth 17

Meth	Compound	NMR	M/z	SM
19	5-Methyl-4-(N-ethyl-N-propylamido)isoxazole	(CDCl ₃) 1.11 (q, 6H), 2.05 (q, 2H), 2.39 (s, 3H), 3.65 (q, 2H) 8.16 (s, 1H)	183	5-Methyl-4-(ethylamino)isoxazole hydrochloride
20	5-Acetyl-1,2-diethylimidazole	(CDCl ₃) 1.35 (m, 6H), 2.45 (s, 3H), 2.73 (q, 2H), 4.30 (q, 2H), 7.73 (s, 1H)	167	Meth 19
21	5-Methyl-4-(methoxyisopropylamino)isoxazole hydrochloride	1.01 (d, 3H), 2.06 (s, 3H), 3.05 (m, 2H), 3.19 (m, 6H), 2.92 (m, 1H), 8.26 (s, 1H)	171	4-Amino-5-methylisoxazole hydrochloride
22	5-Methyl-4-(N-methoxyisopropyl-N-methoxyacetamido)isoxazole	0.90 (d, 3H), 2.35 (s, 3H), 3.20 (m, 8H), 3.60 (s, 2H), 4.80 (m, 1H), 8.40 (m, 1H)	243	Meth 21
23	5-Acetyl-1-methoxyisopropyl-2-methoxymethylimidazole	1.38 (d, 3H), 2.40 (s, 3H), 3.16 (s, 3H), 3.24 (s, 3H), 3.58 (m, 1H), 3.78 (m, 1H), 4.50 (q, 2H), 4.96 (m, 1H), 7.97 (s, 1H)	227	Meth 22
24	5-Methyl-4-(N-propyl-N-methoxyacetamido)isoxazole	0.81 (t, 3H), 1.37 (sext, 2H), 2.34 (s, 3H), 3.18 (s, 3H), 3.42 (t, 2H), 3.71 (s, 2H), 8.65 (s, 1H)	213	Meth 45
25	1-Propyl-2-methoxymethyl-5-acetylimidazole	0.83 (t, 3H), 1.62 (sext, 2H), 2.40 (s, 3H), 3.25 (s, 3H), 4.18 (t, 2H), 4.50 (s, 2H), 7.90 (s, 1H)	197	Meth 24
26	5-Methyl-4-(N-isopropyl-N-2-methylpropylamido)isoxazole	1.02 (br m, 12H), 2.32 (m, 1H), 2.37 (s, 3H), 4.98 (m, 1H), 8.14 (s, 1H)	211	Meth 10

Meth	Compound	NMR	M/z	SM
27	1-Isopropyl-2-isopropyl-5-acetylimidazole	1.38 (d, 6H), 1.55 (d, 6H), 2.43 (s, 3H), 3.17 (m, 1H), 5.18 (m, 1H), 7.78 (s, 1H)	195	Meth 26
28	5-Methyl-4-[N-ethyl-N-(2-methylpropylamido)]isoxazole	1.04 (d, 6H), 1.08 (t, 3H), 2.38 (s, 3H), 2.41 (m, 1H), 3.60 (q, 2H), 8.15 (s, 1H)	197	Meth 16
29	1-Ethyl-2-isopropyl-5-acetylimidazole	1.32 (t, 3H), 1.34 (d, 6H), 2.42 (s, 3H), 3.01 (m, 1H), 4.36 (q, 2H), 7.77 (s, 1H)	182	Meth 28
30	5-Methyl-4-(N-isopropyl-N-ethoxyacetamido)isoxazole	1.0 (m, 9H), 2.34 (s, 3H), 3.34 (m, 2H), 3.61 (s, 2H), 4.73 (m, 1H), 8.58 (s, 1H)		Meth 10
31	1-Isopropyl-2-ethoxymethyl-5-acetylimidazole	1.10 (t, 3H), 1.43 (d, 6H), 2.43 (s, 3H), 3.44 (m, 2H), 4.57 (s, 2H), 4.96 (m, 1H), 7.91 (s, 1H)		Meth 30
32	5-Methyl-4-(N-methyl-N-cyclopropylamido)isoxazole	0.76 (m, 4H), 1.42 (m, 1H), 2.36 (s, 3H), 3.07 (s, 3H), 8.78 (s, 1H)	181	5-Methyl-4-(methylamino)isoxazole hydrochloride
33	1-Methyl-2-cyclopropyl-5-acetylimidazole	0.60 (m, 4H), 1.72 (m, 1H), 2.00 (s, 3H), 3.55 (s, 3H), 7.41 (s, 1H)	165	Meth 32
34	5-Methyl-4-(N-propyl-N-cyclopropylamido)isoxazole	0.80 (m, 7H), 1.35 (m, 3H), 2.32 (s, 3H), 3.45 (t, 2H), 8.76 (s, 1H)	209	Meth 45
35	1-Propyl-2-cyclopropyl-5-acetylimidazole	0.80 (m, 7H), 1.65 (m, 2H), 2.05 (m, 1H), 2.38 (s, 3H), 4.35 (t, 2H), 7.80 (s, 1H)	193	Meth 34

Meth	Compound	NMR	M/z	SM
36	5-Methyl-4-(N-isopropyl-N-cyclopropylamido)isoxazole	0.61 (br s, 2H), 0.76 (br s, 2H), 0.97 (br s, 6H), 1.24 (m, 1H), 2.36 (s, 3H), 4.76 (m, 1H), 8.66 (s, 1H)	209	Meth 10
37	1-Isopropyl-2-cyclopropyl-5-acetylimidazole	0.96 (m, 4H), 1.49 (d, 6H), 2.11 (m, 1H), 2.37 (s, 3H), 5.40 (m, 1H), 7.77 (s, 1H)	193	Meth 36
38	5-Methyl-4-(N-ethyl-N-cyclopropylamido)isoxazole	0.70 (m, 4H), 1.00 (t, 3H), 1.36 (m, 1H), 2.38 (s, 3H), 3.54 (q, 2H), 8.74 (s, 1H)	195	Meth 16
39	1-Ethyl-2-cyclopropyl-5-acetylimidazole	0.86 (m, 2H), 0.97 (m, 2H), 1.23 (t, 3H), 2.04 (m, 1H), 2.36 (s, 3H), 4.39 (q, 2H), 7.78 (s, 1H)	179	Meth 38
40	5-Methyl-4-(N-propyl-N-acetamido)isoxazole	0.81 (t, 3H), 1.37 (m, 2H), 1.75 (s, 3H), 2.34 (s, 3H), 3.42 (t, 2H), 8.67 (s, 1H)	183	Meth 45
41	1-Propyl-2-methyl-5-acetylimidazole	0.83 (t, 3H), 1.60 (m, 2H), 2.37 (m, 6H), 4.17 (t, 2H), 7.83 (s, 1H)	167	Meth 40
42	5-Methyl-4-(N-isopropylformido)isoxazole	Used crude		Meth 10
43	5-Acetyl-1-isopropylimidazole	1.38 (d, 6H), 2.48 (s, 3H), 5.13 (q, 2H), 7.86 (s, 1H), 8.10 (s, 1H)	153	Meth 42
44	5-Methyl-4-(N-propylamido)isoxazole	1.05 (t, 3H), 2.28 (q, 2H), 2.35 (s, 3H), 8.65 (s, 1H), 9.50 (s, 1H)	153 [MH]-	4-amino-5-methylisoxazole hydrochloride

Meth	Compound	NMR	M/z	SM
45	5-Methyl-4-(propylamino)isoxazole	0.90 (t, 3H), 1.62 (m, 2H), 2.53 (s, 3H), 3.10 (t, 2H), 8.68 (s, 1H)	141	Meth 44
46	5-Methyl-4-(N-propionylamido)isoxazole	1.05 (t, 3H), 2.28 (q, 2H), 2.35 (s, 3H), 8.65 (s, 1H), 9.50 (s, 1H)	153 [MH]-	4-amino-5-methylisoxazole hydrochloride
47	5-Methyl-4-(propylamino)isoxazole	0.90 (t, 3H), 1.62 (m, 2H), 2.53 (s, 3H), 3.10 (t, 2H), 8.68 (s, 1H)	141	Meth 46
48	5-Methyl-4-(N-propylformido)isoxazole	0.82 (m, 3H), 1.42 (m, 2H), 2.28 & 2.38 (s, 3H), 3.50 (m, 2H), 8.08 & 8.23 (2s, 1H), 8.62 & 8.72 (s, 1H)	167 [MH]-	Meth 47
49	5-Acetyl-1-propylimidazole	0.76 (t, 3H), 1.63 (m, 2H), 2.40 (s, 3H), 4.28 (t, 2H), 7.90 (s, 1H), 7.95 (s, 1H)	153	Meth 48

Method 50

5-(3-Dimethylaminoprop-2-en-1-yl)-1-isopropyl-2-methoxymethylimidazole

1-Isopropyl-2-methoxymethyl-5-acetylimidazole (Method 12; 3.34g, 17mmol) was dissolved in a mixture of DMF (34ml) and DMF.DEA (11.5ml, 68mmol) and the mixture heated under reflux, under an atmosphere of nitrogen, for 18 hours. The volatiles were removed by evaporation. A solid was precipitated with ether, collected by filtration and air dried to yield the title compound as a brown solid (2.25g, 53%); NMR 1.43 (d, 6H), 2.95 (m, 6H), 3.20 (s, 3H), 4.46 (s, 2H), 5.00 (m, 1H), 5.56 (d, 1H), 7.55 (m, 2H); m/z 252.

10

Methods 51-68

The following compounds were prepared by the procedure of Method 50.

Meth	Compound	NMR	M/z	SM
51 ¹	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-methyl-2-methoxymethylimidazole	2.87 (s, 3H), 3.05 (s, 3H), 3.20 (s, 3H), 3.83 (s, 3H), 4.45 (s, 2H), 5.58 (d, 1H), 7.55 (d, 1H), 7.59 (s, 1H)	224	Meth 7
52 ²	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-methyl-2-ethylimidazole	1.20 (t, 3H), 2.62 (q, 2H), 2.95 (s, 6H), 3.78 (s, 3H), 5.56 (d, 1H), 7.51 (m, 2H)	208	Meth 9
53 ¹	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-methyl-2-isopropylimidazole	1.20 (d, 6H), 3.05 (m, 1H), 3.80 (s, 3H), 5.53 (d, 1H), 7.50 (m, 2H)	222	Meth 14
54	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-ethyl-2-methoxymethylimidazole	1.23 (t, 3H), 2.96 (m, 6H), 3.25 (s, 3H), 4.36 (q, 2H), 4.47 (s, 2H), 5.60 (d, 1H), 7.56 (d, 1H), 7.63 (s, 1H)	222	Meth 18
55	5-(3-Dimethylaminoprop-2-en-1-oyl)-1,2-diethylimidazole	1.20 (m, 6H), 2.65 (q, 2H), 2.96 (brs, 6H), 4.31 (q, 2H), 5.57 (d, 1H), 7.51 (d, 1H), 7.57 (s, 1H)	238	Meth 20
56	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-methoxyisopropyl-2-methoxymethylimidazole	1.40 (d, 3H), 2.95 (m, 6H), 3.16 (s, 3H), 3.24 (s, 3H), 3.63 (m, 1H), 3.89 (m, 1H), 4.47 (q, 2H), 5.00 (m, 1H), 5.58 (d, 1H), 7.75 (m, 2H)	282	Meth 23
57	5-(3-Dimethylaminoprop-2-en-1-oyl)-1,2-dimethylimidazole	2.26 (s, 3H), 2.95 (brs, 6H), 3.8 (s, 3H), 5.56 (d, 1H), 7.52 (m, 2H)	194	³

Meth	Compound	NMR	M/z	SM
58	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-propyl-2-methoxymethylimidazole	0.82 (t, 3H), 1.62 (sext, 2H), 2.7-3.3 (br m, 6H), 3.24 (s, 3H), 4.25 (t, 2H), 4.45 (s, 2H), 5.60 (d, 1H), 7.56 (d, 1H), 7.60 (s, 1H)	252	Meth 25
59	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-isopropylimidazole	1.37 (d, 6H), 1.58 (d, 6H), 2.94 (s, 6H), 3.16 (m, 1H), 5.23 (m, 1H), 5.53 (d, 1H), 7.50 (s, 1H), 7.62 (d, 1H)	250	Meth 27
60	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-ethyl-2-isopropylimidazole	1.19 (t, 3H), 1.21 (d, 6H), 2.48 (s, 6H), 3.03 (m, 1H), 4.33 (q, 2H), 5.57 (d, 1H), 7.55 (d, 1H), 7.57 (s, 1H)	237	Meth 29
61	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-ethoxymethylimidazole	1.10 (t, 3H), 1.28 (d, 6H), 2.99 (m, 6H), 3.41 (m, 2H), 4.52 (s, 2H), 5.51 (m, 1H), 5.59 (d, 1H), 7.58 (d, 2H)	266	Meth 31
62	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-methyl-2-cyclopropylimidazole	0.83 (m, 2H), 0.94 (m, 2H), 1.97 (m, 1H), 2.95 (br s, 6H), 3.91 (s, 3H), 5.55 (d, 1H), 7.50 (m, 2H)		Meth 33
63	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-propyl-2-cyclopropylimidazole	0.80 (m, 7H), 1.65 (m, 2H), 1.95 (m, 1H), 2.95 (br s, 6H), 4.40 (t, 2H), 5.55 (d, 2H), 7.50 (m, 2H)	248	Meth 35
64	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-cyclopropylimidazole	0.91 (m, 4H), 1.49 (d, 6H), 2.04 (m, 1H), 2.93 (m, 6H), 5.51 (m, 2H), 7.40 (s, 1H), 7.51 (d, 1H)	248	Meth 37

Meth	Compound	NMR	M/z	SM
65	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-ethyl-2-cyclopropylimidazole	0.88 (m, 4H), 1.24 (t, 3H), 1.99 (m, 1H), 2.94 (br s, 6H), 4.47 (q, 2H), 5.53 (d, 1H), 7.51 (m, 2H)	234	Meth 39
66	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-propyl-2-methylimidazole	0.82 (t, 3H), 1.60 (m, 2H), 2.32 (s, 3H), 2.95 (br s, 6H), 4.25 (t, 2H), 5.58 (d, 1H), 7.54 (d, 1H), 7.57 (s, 1H)	222	Meth 41
67	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-isopropylimidazole	1.43 (d, 6H), 2.95 (m, 6H), 5.32 (m, 1H), 5.58 (d, 1H), 7.60 (m, 2H), 7.90 (s, 1H)		Meth 43
68	5-(3-Dimethylaminoprop-2-en-1-oyl)-1-propylimidazole	0.75 (t, 3H), 1.65 (m, 2H), 2.95 (br s, 6H), 4.25 (t, 2H), 5.62 (d, 1H), 7.55 (d, 1H), 7.64 (s, 1H), 7.66 (s, 1H)	208	Meth 49

¹ DMF:DMF.DMA (1:1) used as solvent. Purified by flash chromatography on silica gel eluting with DCM/ 2% methanolic ammonia (100:0 increasing in polarity to 95:5).

² DMF.DMA used as solvent

³ Starting material (2-methyl-4-acetylimidazole) was synthesized according to Tetrahedron letters 1985, 26 (29), 3423-3426.

Method 69

2-Anilino-4-(1-isopropyl-2-methoxymethylimidazol-5-yl)pyrimidine

5-(3-Dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-methoxymethylimidazole (Method 50; 1.26g, 5mmol), phenylguanidine hydrogen carbonate (1.09g, 5.5mmol) and sodium methoxide (594mg, 11mmol) were suspended in anhydrous DMA (10ml) and the mixture heated at 110°C for 3 hours. The volatiles were evaporated in vacuo the residues was suspended in water (50ml). The solution was extracted DCM (3 x 50ml). The combined extracts were washed with water (50ml) and then brine (50ml), dried and the volatiles removed by evaporation. The residue was purified by flash silica chromatography eluting with DCM:MeOH (100:0 increasing in polarity to 97:3) to give the title compound as brown oil.

NMR: 1.43 (d, 6H), 3.30 (s, 3H), 4.56 (s, 2H), 5.54 (m, 1H), 6.96 (t, 1H), 7.05 (d, 1H), 7.24 (t, 2H), 7.44 (s, 1H), 7.65 (d, 2H), 8.41 (d, 1H), 9.42 (s, 1H); m/z 324.

Methods 70-84

5 The following compounds were prepared by the procedure of Method 69.

Meth	Compound	NMR	M/z	SM
70	2-Anilino-4-(1-methyl-2-methoxymethylimidazol-5-yl)pyrimidine	3.30 (s, 3H), 3.99 (s, 3H), 4.50 (s, 2H), 6.94 (t, 1H), 7.13 (d, 1H), 7.28 (t, 2H), 7.65 (s, 1H), 7.69 (d, 2H), 8.41 (d, 1H), 9.48 (s, 1H)	296	Meth 51
71	2-Anilino-4-(1-methyl-2-isopropylimidazol-5-yl)pyrimidine	1.36 (d, 6H), 3.08 (m, 1H), 3.96 (s, 3H), 6.94 (d, 1H), 7.05 (t, 1H), 7.19 (s, 1H), 7.37 (t, 2H), 7.53 (s, 1H), 7.58 (d, 2H), 8.36 (d, 1H)	294	Meth 53
72	2-Anilino-4-(1-ethyl-2-methoxymethylimidazol-5-yl)pyrimidine	1.17 (t, 3H), 3.28 (s, 3H), 4.51 (s, 2H), 4.60 (q, 2H), 6.97 (t, 1H), 7.16 (d, 1H), 7.29 (t, 2H), 7.64 (d, 2H), 7.71 (s, 1H), 8.40 (d, 1H), 9.40 (s, 1H)	310	Meth 54
73	2-Anilino-4-(1,2-diethylimidazol-5-yl)pyrimidine	1.15 (t, 3H), 1.27 (t, 3H), 2.72 (q, 2H), 4.53 (q, 2H), 6.96 (t, 1H), 7.11 (d, 1H), 7.28 (t, 2H), 7.64 (m, 3H), 8.33 (d, 1H), 9.34 (s, 1H)	294	Meth 55
74	2-Anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine	2.37 (s, 3H), 3.93 (s, 3H), 6.95 (t, 1H), 7.08 (d, 1H), 7.28 (t, 2H), 7.59 (s, 1H), 7.69 (d, 2H), 8.35 (d, 1H), 9.43 (s, 1H)	266	Meth 57

Meth	Compound	NMR	M/z	SM
75	2-Anilino-4-(1-propyl-2-methoxymethylimidazol-5-yl)pyrimidine	(400 MHz), 0.67 (t, 3H), 1.53 (sext, 2H), 3.30 (s, 3H), 4.54 (m, 4H), 7.00 (t, 1H), 7.15 (d, 1H), 7.32 (t, 2H), 7.64 (d, 2H), 7.70 (s, 1H), 8.42 (d, 1H), 9.43 (s, 1H)	324	Meth 58
76	2-Anilino-4-(1-isopropyl-2-isopropylimidazol-5-yl)pyrimidine	1.23 (d, 6H), 1.43 (d, 6H), 3.22 (m, 1H), 5.61 (m, 1H), 6.96 (t, 1H), 7.01 (d, 1H), 7.26 (t, 2H), 7.42 (s, 1H), 7.64 (d, 2H), 8.38 (d, 1H), 9.39 (br s, 1H)	323	Meth 59
77	2-Anilino-4-(1-ethyl-2-isopropylimidazol-5-yl)pyrimidine	1.23 (t, 3H), 1.38 (d, 6H), 3.05 (m, 1H), 4.50 (q, 2H), 6.94 (d, 1H), 7.06 (t, 1H), 7.34 (t, 2H), 7.56 (d, 2H), 7.58 (s, 1H), 8.32 (d, 1H)	309	Meth 60
78	2-Anilino-4-(1-isopropyl-2-ethoxymethylimidazol-5-yl)pyrimidine	1.12 (t, 3H), 1.46 (d, 6H), 3.49 (m, 2H), 4.58 (s, 2H), 5.54 (m, 1H), 6.97 (t, 1H), 7.06 (d, 1H), 7.28 (t, 2H), 7.45 (s, 1H), 7.66 (d, 2H), 8.42 (d, 1H), 9.43 (s, 1H)	338	Meth 61
79	2-Anilino-4-(1-methyl-2-cyclopropylimidazol-5-yl)pyrimidine	0.83 (m, 2H), 0.94 (m, 2H), 2.08 (m, 1H), 4.04 (s, 3H), 6.93 (t, 1H), 7.09 (d, 1H), 7.27 (t, 2H), 7.51 (s, 1H), 7.70 (d, 2H), 8.38 (d, 1H), 9.40 (s, 1H)	292	Meth 62

Meth	Compound	NMR	M/z	SM
80	2-Anilino-4-(1-propyl-2-cyclopropylimidazol-5-yl)pyrimidine	0.70 (t, 3H), 0.90 (m, 4H), 1.55 (m, 2H), 2.06 (m, 1H), 4.63 (t, 2H), 6.93 (t, 1H), 7.06 (d, 1H), 7.27 (t, 2H), 7.56 (s, 1H), 7.70 (d, 2H), 8.32 (d, 1H), 9.35 (s, 1H)	320	Meth 63
81	2-Anilino-4-(1-isopropyl-2-cyclopropylimidazol-5-yl)pyrimidine	0.96 (m, 4H), 1.53 (d, 6H), 2.13 (m, 1H), 5.80 (m, 1H), 6.99 (m, 2H), 7.28 (t, 2H), 7.37 (s, 1H), 7.67 (d, 2H), 8.36 (d, 1H), 9.40 (s, 1H)	320	Meth 64
82	2-Anilino-4-(1-ethyl-2-cyclopropylimidazol-5-yl)pyrimidine	0.92 (m, 4H), 1.23 (t, 3H), 2.07 (m, 1H), 4.69 (q, 2H), 6.98 (t, 1H), 7.08 (d, 1H), 7.29 (t, 2H), 7.57 (s, 1H), 7.65 (d, 2H), 8.33 (d, 1H), 9.33 (s, 1H)	306	Meth 65
83	2-Anilino-4-(1-propyl-2-methylimidazol-5-yl)pyrimidine	0.66 (t, 3H), 1.51 (m, 2H), 2.39 (s, 3H), 4.49 (t, 2H), 6.99 (t, 1H), 7.09 (d, 1H), 7.62 (s, 1H), 7.65 (d, 2H), 8.36 (d, 1H), 9.38 (s, 1H)	294	Meth 66
84	2-Anilino-4-(1-propylimidazol-5-yl)pyrimidine	0.68 (t, 3H), 1.55 (m, 2H), 4.48 (t, 2H), 6.97 (t, 1H), 7.14 (d, 1H), 7.30 (t, 2H), 7.63 (d, 2H), 7.73 (s, 1H), 7.88 (s, 1H), 8.38 (d, 1H), 9.40 (s, 1H)	280	Meth 68

Method 85

2-Amino-4-(1-methoxyisopropyl-2-methoxymethylimidazol-5-yl)pyrimidine

5-(3-Dimethylaminoprop-2-en-1-yl)-1-methoxyisopropyl-2-methoxymethylimidazole

5 (Method 56; 3.13, 11.1mmol) and guanidine hydrochloride (2.65 g, 27.8mmol) were

suspended in 1-butanol (20ml). Sodium methoxide (2.4g, 44mmol) was added in one portion and the mixture heated under reflux, under an atmosphere of nitrogen, for 18 hours. The volatiles were removed by evaporation. Water (50ml) was added and extracted EtOAc (3 x 50ml). The organic layers were combined and dried with Chemelut CE1010 and the solvent evaporated in vacuo. The residue was purified by flash silica chromatography eluting with DCM:MeOH (100:0 increasing in polarity to 95:5) to give the title compound as an orange solid (1.86g, 60%). NMR: 1.43 (d, 3H), 3.16 (s, 3H), 3.24 (s, 3H), 3.63 (m, 1H), 3.89 (m, 1H), 4.50 (q, 2H), 5.26 (m, 1H), 6.57 (s, 2H), 6.80 (d, 1H), 7.40 (s, 1H), 8.21 (d, 1H); m/z 278.

10 Methods 86-88

The following compounds were prepared by the procedure of Method 85.

Meth	Compound	NMR	M/z	SM
86	2-Amino-4-(1-methyl-2-ethylimidazol-5-yl)pyrimidine	1.21 (t, 3H), 2.69 (q, 2H), 3.92 (s, 3H), 6.52 (brs, 2H), 6.81 (d, 1H), 7.48 (s, 1H), 8.15 (d, 1H)	203	Meth 52
87	2-Amino-4-(1-propyl-2-methylimidazol-5-yl)pyrimidine	0.82 (t, 3H), 1.59 (q, 2H), 2.38 (s, 3H), 4.42 (t, 2H), 6.45 (s, 2H), 6.82 (d, 1H), 7.50 (s, 1H), 8.20 (d, 1H)	218	Meth 66
88	2-Amino-4-(1-isopropylimidazol-5-yl)pyrimidine	1.53 (d, 6H), 5.05 (s, 2H), 5.59 (sept, 1H), 6.85 (d, 1H), 7.56 (s, 1H), 7.78 (s, 1H), 8.23 (d, 1H)	204	Meth 67

Method 89

15 2-Anilino-4-(1-methyl-2-n-butylimidazol-5-yl)pyrimidine

2-Anilino-4-(1,2-dimethylimidazol-5-yl)pyrimidine (Method 74; 2g, 7.55mmol) was dissolved in anhydrous THF (100ml) at RT under a nitrogen atmosphere. The stirring solution was cooled using dry-ice/acetone bath to -70°C. A 1.6M solution of n-butyl lithium in hexane (6.3ml, 10.08mmol) was added drop-wise keeping temperature <-60°C until the dark red colour remained. One more equivalent of n-butyl lithium in hexane (4.7ml, 7.55mmol), was then added dropwise keeping the temperature below -60°C. At this point the solution stirred at -70°C for 10 minutes when propyl iodide (809µl, 8.29mmol) was added, the temperature was

maintained at -70°C for an additional 10 minutes then allowed to rise to RT. The reaction was allowed to stir for 1hr at room temperature when water (100ml) was added. The aqueous layer extracted with EtOAc (2 x 20ml). Organics were combined, dried solvent evaporated in vacuo. The residue was purified by flash silica chromatography DCM:MeOH (95:5) to yield the title compound (1.03g, 45%) as a pure white solid. NMR: 0.90 (t, 3H), 1.39 (m, 2H), 1.66 (m, 2H), 2.70 (t, 2H), 3.94 (s, 3H), 6.95 (t, 1H), 7.08 (d, 1H), 7.28 (t, 2H), 7.65 (d, 2H), 7.59 (s, 1H), 8.35 (d, 1H), 9.42 (s, 1H); m/z 308.

Methods 90-102

The following compounds were prepared by the procedure of Method 89.

Meth	Compound	NMR	M/z	SM
90	2-Anilino-4-[1-methyl-2-(2-hydroxy-3,3-dimethylbutyl)imidazol-5-yl]pyrimidine	0.9 (s, 3H), 2.65 (m, 1H), 2.84 (m, 1H), 3.60 (m, 1H), 3.98 (s, 3H), 4.83 (d, 1H), 6.97 (t, 1H), 7.10 (d, 1H), 7.28 (dd, 2H), 7.63 (s, 1H), 7.71 (d, 2H), 8.38 (d, 1H), 9.45 (d, 1H)	352	Pivaldehyde
91	2-Anilino-4-(1-methyl-2-propylimidazol-5-yl)pyrimidine	0.95 (t, 3H), 1.70 (m, 2H), 2.68 (t, 2H), 3.92 (s, 3H), 6.95 (t, 1H), 7.08 (d, 1H), 7.28 (t, 2H), 7.60 (s, 1H), 7.69 (d, 2H), 8.34 (d, 1H), 9.44 (s, 1H)	294	Ethyl Iodide + Meth 74
92	2-Anilino-4-[1-methyl-2-(2-methoxyethyl)imidazol-5-yl]pyrimidine	2.96 (t, 2H), 3.26 (s, 3H), 3.70 (t, 2H), 3.95 (s, 3H), 6.94 (t, 1H), 7.09 (s, 1H), 7.26 (t, 2H), 7.60 (s, 1H), 7.74 (d, 2H), 8.38 (s, 1H), 9.44 (s, 1H)	309	Chloro-methyl-methylether + Meth 74

Meth	Compound	NMR	M/z	SM
93	2-Anilino-4-(1-ethyl-2-propylimidazol-5-yl)pyrimidine	0.96 (t, 3H), 1.15 (t, 3H), 1.70 (m, 2H), 2.68 (t, 2H), 4.54 (q, 2H), 6.97 (t, 1H), 7.10 (d, 1H), 7.29 (t, 2H), 7.65 (m, 3H), 8.34 (d, 1H), 9.35 (s, 1H)	308	Ethyl Iodide + Ex 28 WO 02/20512
94	2-Anilino-4-(1-ethyl-2-butylimidazol-5-yl)pyrimidine	0.92 (t, 3H), 1.14 (t, 3H), 1.38 (m, 2H), 1.68 (m, 2H), 2.70 (t, 2H), 4.56 (q, 2H), 6.98 (t, 1H), 7.08 (d, 1H), 7.26 (t, 2H), 7.64 (m, 3H), 8.37 (d, 1H), 9.36 (s, 1H)	322	Propyl Iodide + Ex 28 WO 02/20512
95	2-Anilino-4-(1-isopropyl-2-propylimidazol-5-yl)pyrimidine	1.98 (t, 3H), 1.4 (d, 6H), 1.78 (m, 2H), 2.76 (t, 2H), 5.62 (m, 1H), 6.97 (t, 1H), 7.02 (d, 1H), 7.30 (t, 2H), 7.44 (s, 1H), 7.66 (d, 2H), 8.39 (d, 1H), 9.40 (s, 1H)	322	Ethyl Iodide + Ex 32 WO 02/20512
96	2-Anilino-4-(1-isopropyl-2-ethylimidazol-5-yl)pyrimidine	1.26 (t, 3H), 1.44 (d, 6H), 2.80 (q, 2H), 5.62 (m, 1H), 6.97 (t, 1H), 7.02 (d, 1H), 7.26 (t, 2H), 7.42 (s, 1H), 7.64 (s, 2H), 8.39 (d, 1H), 9.39 (s, 1H)	308	Methyl Iodide + Ex 32 WO 02/20512
97	2-Anilino-4-(1-methyl-2-(2-hydroxypropyl)imidazol-5-yl)pyrimidine	No NMR data	324	Acetone + Ex 5 WO 02/20512

Meth	Compound	NMR	M/z	SM
98	2-{4-[<i>N</i> -(2-methoxyethyl)- <i>N</i> -(<i>t</i> -butyl)sulphamoyl]anilino}-4-(1-ethyl-2-(2-methyl-2-hydroxypropyl)imidazol-5-yl)pyrimidine	1.22-1.10 (m, 18H), 2.82 (s, 2H), 3.28 (s, 3H), 3.55-3.42 (m, 4H), 4.79 (q, 2H), 4.94 (s, 1H), 7.22 (d, 1H), 7.75-7.70 (m, 3H), 7.88 (d, 2H), 8.42 (d, 1H), 9.88 (s, 1H).	531	Acetone + Meth 107
99	2-Anilino-4-(1,2-dipropyl-imidazol-5-yl)pyrimidine	No NMR data	322	Ethyl iodide + Meth 83
100	4-(2-But-3-enyl-1-propylimidazol-5-yl)-2-{4-[<i>N</i> -(2-methoxyethyl)- <i>N</i> -(2-trimethylsilylethoxymethyl), sulphamoyl]anilino}pyrimidine	No NMR data	601	Allyl bromide + Meth 108
101 ¹	4-[2-(3,3-Dimethyl-2-hydroxybut-1-yl)-1-(propyl)imidazol-5-yl]-2-anilinopyrimidine	0.64 (t, 3H), 0.97 (s, 9H), 1.58-1.42 (m, 2H), 3.59 (s, 1H), 4.52-4.41 (m, 1H), 4.63-4.58 (m, 1H), 4.90 (s, 1H), 6.99 (t, 1H), 7.10 (d, 1H), 7.30 (t, 2H), 7.63-7.60 (m, 3H), 8.39 (d, 2H), 9.39 (s, 1H).	380	Pivaldehyde + Meth 83
102 ¹	4-{2-[2-(4-Chlorophenyl)ethyl]-1-(methyl)imidazol-5-yl}-2-anilinopyrimidine	3.02 (s, 4H), 3.90 (s, 3H), 6.97 (t, 1H), 7.09 (d, 1H), 7.30 (m, 6H), 7.64 (s, 1H), 7.70 (d, 2H), 8.38 (d, 1H), 9.42 (s, 1H)	390	4-chlorobenzyl bromide + Meth 74

¹ Purified by chromatography on silica eluting with 2%MeOH/EtOAc

Method 103**2-Anilino-4-(1-methyl-2-(3,3-dimethylbut-1-enylimidazol-5-yl)pyrimidine**

2-Anilino-4-[1-methyl-2-(2-hydroxy-3,3-dimethylbutyl)imidazol-5-yl]pyrimidine (Method 90; 988mg, 2.8mmol) was dissolved in DCM (20ml). To this was added triethylamine (1.18ml, 8.4mmol) followed by methanesulphonyl chloride (458µl, 5.92mmol) in portions. After 18 hr the volatiles were evaporated in vacuo and the residue resuspended in toluene (20ml). To this stirred solution was added 1,8-diazabicyclo[5.4.0]undec-7-ene (4ml, 26.7mmol) and heated to reflux for 1hr. Volatiles evaporated in vacuo and the residue was triturated with water. The resultant solid was collected by filtration, washed with water (20ml) and dried under vacuum at 60°C to yield the title compound (830mg, 90%). NMR 1.15 (s, 9H), 4.04 (s, 3H), 6.38 (d, 1H), 6.8 (d, 1H), 6.96 (t, 1H), 7.12 (d, 1H), 7.28 (t, 2H), 7.71 (m, 3H), 8.38 (d, 1H), 9.48 (s, 1H); m/z 334.

Method 104**2-Anilino-4-[1-methyl-2-(3,3-dimethylbutylimidazol-5-yl)pyrimidine**

To a solution of 2-anilino-4-(1-methyl-2-(3,3-dimethylbut-1-enylimidazol-5-yl)pyrimidine (Method 103; 200mg, 0.6mmol) in EtOH (20ml) was added 10% Pd/C (100mg) and stirred under a hydrogen atmosphere for 3 days. The reaction mixture was passed through a pad of celite to remove the catalyst and the filtrate evaporated in vacuo. The residue was triturated with ether to give the title compound 105mg (53%). NMR 0.97 (s, 9H), 1.60 (m, 2H), 2.67 (m, 2H), 3.97 (s, 3H), 6.98 (t, 1H), 7.08 (d, 1H), 7.27 (dd, 2H), 7.60 (s, 1H), 7.70 (d, 2H), 8.39 (d, 1H), 9.42 (s, 1H); m/z 336.

Method 105**4-(2-Formyl-1-isopropylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxymethyl)sulphamoyl]anilino}pyrimidine**

4-(1-Isopropylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxymethyl)sulphamoyl]anilino}pyrimidine (Method 106; 1.22g, 2.33mmol), was dissolved in anhydrous THF (70ml), under nitrogen. The solution was cooled to -78°C and *n*-butyl lithium (3.48 ml of a 1.6 N solution in hexanes, 5.57mmol), was added slowly, maintaining the temperature at less than -65°C. The reaction mixture was then stirred at -78°C for 30 minutes, then DMF (345µl, 4.46mmol), was added and mixture allowed to warm to

ambient temperature and stirred for 1 hour. The reaction mixture was then poured into water (100ml), and extracted with EtOAc (2 x 50ml). The organic extracts were combined, washed with water (50ml), brine (50ml), and dried. The volatiles were removed and the residue was purified by chromatography on silica gel eluting with 3% MeOH in DCM, to give the title product, (307 mg, 24%), as a pale yellow foam. NMR: 0.02 (s, 9H), 0.83 (dd, 2H), 1.63 (d, 6H), 3.28 (s, 3H), 3.37 (t, 2H), 3.42 (dd, 2H), 3.52 (t, 2H), 4.78 (s, 2H), 5.71 (m, 1H), 7.40 (d, 1H), 7.82 (d, 2H), 7.92 (s, 1H), 8.01 (d, 2H), 8.78 (d, 1H), 9.91 (s, 1H); m/z: 573 [MH]⁺.

Method 106

4-(1-Isopropylimidazol-5-yl)-2-[4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxymethyl) sulphonamoyl]anilino]pyrimidine

Sodium *t*-butoxide (1.42g, 14.78mmol), was added to a stirred solution of 2-amino-4-(1-isopropylimidazol-5-yl)pyrimidine (Method 88; 2.0g, 9.85mmol), *N*-(2-methoxyethyl)-*N*-(2-trimethylsilylethoxymethyl)-4-iodobenzenesulphonamide (Method 112; 5.11g, 10.84 mmol), tris(dibenzylideneacetone), dipalladium (0), (650mg, 0.71mmol), and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (470mg, 0.75mmol), in dioxane (180ml), and the mixture heated at 80°C overnight. The reaction was cooled to ambient temperature and acetic acid (282μl, 4.93mmol), added. The reaction mixture was poured into water (70ml), and extracted with EtOAc (3 x 40ml). The organic extracts were combined, washed with water (2 x 40ml), saturated brine (40ml), dried, and the solvent removed by evaporation. The residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (97:3), and then by chromatography on silica gel eluting with DCM/MeOH (98.5:1.5), to yield the title compound (1.95g, 36%). NMR: 0.01 (s, 9H), 0.85 (dd, 2H), 1.53 (d, 6H), 3.26 (s, 2H), 3.37 (t, 2H), 3.44 (dd, 2H), 3.52 (t, 1H), 4.79 (s, 2H), 5.57 (m, 1H), 7.36 (d, 1H), 8.80 (m, 3H), 7.98 (d, 2H), 8.19 (s, 1H), 8.58 (d, 1H), 10.13 (s, 1H); m/z: 545 [MH]⁺.

Methods 107-108

The following compounds were prepared by an analogous procedure to Method 106.

Meth	Compound	NMR	M/z	SM
107	4-(1-Ethyl-2-methylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-t-butylsulphamoyl]anilino}pyrimidine	1.15-1.22 (m, 12H), 2.40 (s, 3H), 3.24-3.28 (m, 3H), 3.46-3.55 (m, 4H), 4.59 (q, 2H), 7.20 (d, 1H), 7.68 (s, 1H), 7.70 (d, 2H), 7.89 (d, 2H), 8.42 (d, 1H), 9.84 (s, 1H)	473	Meth 27 WO 02/20512 + Meth 113
108	4-(2-Methyl-1-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)-N-(2-trimethylsilylethoxy methyl)sulphamoyl]anilino}pyrimidine	No NMR data	559 [MH] ⁺	Meth 87 + Meth 112

Method 109**4-(1-Methyl-2-(2-methylpropyl)imidazol-5-yl)-2-anilinopyrimidine**

4-(1-Methyl-2-(2-methylprop-1-enyl)imidazol-5-yl)-2-anilinopyrimidine (Method 110; 400mg, 1.3mmol), and 10% Pd on C catalyst (150mg), in ethanol (50ml), was hydrogenated at 40C and 20bar for 18 hours. The catalyst was removed by filtration and the filter pad washed with ethanol. The solvent was evaporated and the residue triturated with ether and collected by filtration to give the title compound (280mg, 71%). M/z: 308.

Method 110**4-(1-Methyl-2-(2-methylprop-1-enyl)imidazol-5-yl)-2-anilinopyrimidine**

Methanesulphonyl chloride (151µl, 1.96mmol), was added to a solution of 2-anilino-4-(1-methyl-2-(2-methyl-2-hydroxypropyl)imidazol-5-yl)pyrimidine (Method 97; 600mg, 1.86mmol), and triethylamine (777µl, 5.58mmol), in DCM (10ml), at ambient temperature under nitrogen. The mixture was stirred for 3 hours then adsorbed directly onto silica gel and purified by chromatography eluting with EtOAc to give the title compound (235mg, 42%). NMR: 1.98 (s, 3H), 2.14 (s, 3H), 3.99 (s, 3H), 6.24 (s, 1H), 6.98 (t, 1H), 7.10 (d, 1H), 7.28 (dd, 2H), 7.69-7.72 (m, 3H), 8.40 (d, 1H), 9.42 (s, 1H); m/z: 306.

Method 111

The following compounds were prepared by an analogous procedure to Method 110.

Meth	Compound	M/z	SM
111	4-[2-(2-Methylprop-1-enyl)-1-ethylimidazol-5-yl]-2-{4-[N-(2-methoxyethyl)-N-t-butylsulphamoyl]anilino}pyrimidine	513	Meth 98

Method 112

5 *N*-(2-Methoxyethyl)-*N*-(2-trimethylsilylethoxymethyl)-4-iodobenzenesulphonamide

Sodium hydride (2.2g, 55mmol), was added to a solution of *N*-(2-methoxyethyl)-4-iodobenzenesulphonamide (Method 4; 15.8g, 46.3mmol), in DMF (250ml), under nitrogen at 0°C and the mixture stirred for 1 hour. 2-Trimethylsilylethoxymethyl chloride (10g, 60mmol), was added and the mixture stirred overnight at ambient temperature. The volatiles were removed by evaporation and the residue dissolved in ether, washed with water and then brine, dried (Na₂SO₄), and the solvent evaporated to give the title compound (22.6g, 74%). NMR: 0.2 (s, 9H), 0.89 (t, 2H), 3.30 (s, 3H), 3.40-3.36 (m, 2H), 3.59-3.43 (m, 2H), 4.82 (s, 2H), 7.60 (d, 2H), 7.84 (d, 2H).

15 **Method 113**

N-(2-Methoxyethyl)-*N*-(*t*-butyl)-4-iodobenzenesulphonamide

Sodium hydride (71mg, 1.77mmol), was added to a solution of *N*-*t*-butyl-4-iodobenzenesulphonamide (Method 5; 500mg, 1.47mmol), in anhydrous DMF (15ml), under nitrogen at 0°C. The resulting suspension was stirred at 0°C for 30 minutes. A solution of 1-bromo-2-methoxyethane (167μl, 1.77mmol), and sodium iodide (265mg, 1.77mmol), in DMF (15ml), (pre-stirred at ambient temperature for 1hr), was then added dropwise to the mixture while the, reaction temperature was maintained at 0°C and the mixture stirred for 10 minutes. The mixture was allowed to warm to ambient temperature, and then heated at 60°C for 20 hours. A further solution of 1-bromo-2-methoxyethane (167μl, 1.77mmol), and sodium iodide (265mg, 1.77mmol), in DMF (15ml), (pre-stirred at ambient temperature for 1hr), was then added dropwise to the mixture at ambient temperature and the reaction mixture was heated at 60°C for 20 hours. The mixture was cooled and solvent removed by evaporation. The residue was dissolved in ether (25ml), washed with 10% aqueous sodium hydroxide solution (20ml), water (3 x 25ml), and dried. The volatiles were removed by evaporation and the residue

purified by flash chromatography on silica gel eluting with DCM to yield the title product as a clear oil that crystallised on standing (147 mg, 25%), NMR: 1.23 (s, 9H), 3.24 (s, 3H), 3.48 (s, 4H), 7.57 (d, 2H), 7.94 (d, 2H).

5 **Method 114**

4-[2-(3,3-Dimethylbut-1-en-1-yl)-1-(propyl)imidazol-5-yl]-2-anilinopyrimidine

Triethylamine (0.74ml, 5.05mmol), followed by methane sulphonyl chloride (0.103ml, 1.33mmol) was added to a stirred solution of 4-[2-(3,3-dimethyl-2-hydroxybut-1-yl)-1-(propyl)imidazol-5-yl]-2-anilinopyrimidine (Method 101; 480mg, 1.26mmol) in DCM (40 ml) at ambient temperature and the mixture stirred for 24 hours. The volatiles were removed by evaporation and toluene (10ml), and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.38ml, 2.54mmol) was added to the residue. The mixture was heated at reflux for 5 hours, allowed to cool, washed with water and extracted with EtOAc. The extracts were combined, dried and the solvent removed by evaporation to give the title compound (240mg, 53%). NMR: 0.64 (t, 3H), 1.15 (s, 9H), 1.53 (q, 2H), 4.64 (t, 2H), 6.38 (d, 1H), 6.80 (d, 1H), 6.99 (t, 1H), 7.10 (d, 1H), 7.28 (t, 2H), 7.62 (d, 3H), 7.75 (s, 1H), 8.38 (d, 1H), 9.38 (s, 1H); m/z 362.

Method 115

4-[2-(3,3-Dimethylbutyl)-1-(propyl)imidazol-5-yl]-2-anilinopyrimidine

A mixture of 10% palladium on charcoal catalyst (100mg), 4-[2-(3,3-dimethylbut-1-en-1-yl)-1-(propyl)imidazol-5-yl]-2-anilinopyrimidine (Method 114; 230mg, 0.64mmol) in ethanol (50ml) was stirred under an atmosphere of hydrogen for 72 hours. The catalyst was removed by filtration through diatomaceous earth, and the filter pad washed with warm MeOH. The solvent removed by evaporation to give the title compound (200mg, 86%). M/z 364.

Method 116

4-[2-(Chloromethyl)-1-(propyl)imidazol-5-yl]-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine

Chlorosulphonic acid (2.29g, 20mmol) was added dropwise to a stirred solution of 2-anilino-4-(1-propyl-2-methoxymethylimidazol-5-yl)pyrimidine (Method 75; 1.29g, 4.0mmol) in thionyl chloride (30ml), cooled to 0-4°C. The solution was allowed to warm to ambient

temperature and was then heated under reflux for 18 hour. The mixture was cooled and an oil separated out. The excess thionyl chloride was decanted from this oil, and the residue was washed with thionyl chloride (10ml) and any volatiles removed by evaporation. The residue was dissolved in MeOH (15ml), cooled to 0-4°C and a solution of 2-ethoxyethylamine (3.56g, 40mmol) in cold MeOH (15ml) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for one hour. The mixture was allowed to stand and cooled to 0-4°C. The resulting crystalline product was collected by filtration, washed with MeOH and dried to give the title compound (587mg, 31%). NMR: 0.70 (t, 3H), 1.05 (t, 3H), 1.55 (m, 2H), 2.86 (m, 2H), 3.33 (m, 4H), 4.60 (t, 2H), 4.95 (s, 2H), 7.25 (d, 1H), 7.46 (t, 1H), 7.71 (d, 2H), 7.75 (s, 1H), 7.86 (d, 2H), 8.50 (d, 1H), 9.90 (s, 1H); m/z 479.

Method 117

4-{2-[2-(4-Chlorophenyl)ethyl]-1-(methyl)imidazol-5-yl}-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine

4-{2-[2-(4-Chlorophenyl)ethyl]-1-(methyl)imidazol-5-yl}-2-anilinopyrimidine (Method 102) was treated with 2-methoxyethylamine by the conditions described in Method 116. The crude product was purified by chromatography on silica gel eluting with DCM / MeOH (98:2) to give the title compound (164mg, 48%) as glassy solid. NMR: 2.88 (q, 2H), 3.02 (s, 4H), 3.15 (s, 3H), 3.26 (m, 2H), 3.92 (s, 3H), 7.21 (d, 1H), 7.32 (d, 4H), 7.44 (s, 1H), 7.66 (s, 1H), 7.68 (d, 2H), 7.90 (d, 2H), 8.44 (d, 1H), 9.92 (s, 1H); m/z 528.

Method 118

2-Anilino-4-(2-formyl-1-propylimidazol-5-yl)pyrimidine

2-Anilino-4-(1-propylimidazol-5-yl)pyrimidine (Method 84) was treated as described in Method 105. The crude product was purified by chromatography on silica gel eluting with EA/IsoHex) (80:20) to give the title compound (1.051g, 48%) as a yellow solid. NMR: 0.63 (t, 3H), 1.59 (m, 2H), 4.94 (t, 2H), 7.01 (t, 1H), 7.30 (m, 3H), 7.63 (d, 2H), 8.0 (s, 1H), 8.55 (d, 1H), 9.60 (s, 1H), 9.80 (s, 1H).

Method 119**2-Anilino-4-(2-dimethylaminomethyl-1-propylimidazol-5-yl)pyrimidine**

A mixture of 2-anilino 4-(2-formyl-1-propylimidazol-5-yl)pyrimidine (Method 118; 200mg, 0.65mmol) and dimethylamine (391µl of 2M solution in THF, 0.78mmol) in MeOH (6ml) stirred for 3 hours at ambient temperature. Acetic acid (41mg, 0.716mmol) and sodium cyanoborohydride (45mg, 0.716mmol) were added and the mixture stirred for a further 18 hours. The volatiles were removed by evaporation and residue dissolved in EtOAc (7ml). This solution was washed with saturated aqueous sodium hydrogen carbonate solution, water, and brine, then dried and the solvent removed by evaporation to give the title compound (210mg, 96%) as a yellow foam. NMR: 0.62 (t, 6H), 1.50 (m, 2H), 2.23 (s, 6H), 3.60 (s, 2H), 4.56 (m, 2H), 6.98 (t, 1H), 7.10 (d, 1H), 7.28 (t, 2H), 7.62 (m, 3H), 8.39 (d, 1H), 9.39 (s, 1H); m/z 337.

Method 120**2-Anilino 4-(2-ethylamniomethyl-1-propylimidazol-5-yl)pyrimidine**

2-Anilino 4-(2-formyl-1-propylimidazol-5-yl)pyrimidine (Method 118) was treated with ethylamine (2M solution in MeOH) by the procedure of Method 119 to give the title compound (185mg, 93%) as a yellow foam. M/z 337.

Example 87

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof (hereafter compound X), for therapeutic or prophylactic use in humans:-

(a): Tablet I	mg/tablet
Compound X	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b): Tablet II	mg/tablet
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c): Tablet III	mg/tablet
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d): Capsule	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5

(e): Injection I	(50 mg/ml)
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	(to adjust pH to 7.6)
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

(f): Injection II	10 mg/ml
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%


(g): Injection III	(1mg/ml,buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

Note

- 5 The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

1. A compound of formula (I):



(I)

wherein:

R^1 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 0-2; wherein the values of R^1 may be the same or different;

R^2 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl,

- 10 C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclyl or heterocyclyl C_{1-3} alkyl; wherein R^2 may be optionally substituted on carbon by one or more hydroxy, methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

- 15 R^3 is hydrogen, halo or cyano;

R^4 is C_{1-6} alkyl or C_{1-6} alkoxy C_{1-6} alkyl;

R^5 is substituted methyl, optionally substituted C_{2-6} alkyl, C_{3-6} cycloalkyl or optionally substituted C_{2-6} alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenyl, methylamino, ethylamino, dimethylamino, diethylamino, methylthio, ethylthio, propylthio, isopropylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl, methylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

- 25 provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofuran-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropylimidazol-5-yl)-2-{4-

[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(tetrahydrofuran-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine.

10 2. A compound of formula (I) according to claim 1 wherein p is 0; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

3. A compound of formula (I) according to either claim 1 or claim 2 wherein R² is hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl or
15 heterocyclC₁₋₃alkyl; wherein R² may be optionally substituted on carbon by one or more hydroxy, methoxy, ethoxy or trifluoromethyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

4. A compound of formula (I) according to any one of claims 1-3 wherein R³ is
20 hydrogen; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

5. A compound of formula (I) according to any one of claims 1-4 wherein R⁴ is C₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

25

6. A compound of formula (I) according to any one of claims 1-5 wherein R⁵ is substituted methyl, optionally substituted C₂₋₆alkyl, C₃₋₆cycloalkyl or optionally substituted C₂₋₆alkenyl; wherein said substituents are selected from one or more hydroxy, methoxy, ethoxy, isopropoxy, phenyl, ethylamino, dimethylamino, methylthio, ethylthio, isopropylthio, ethylsulphinyl or ethylsulphonyl; or a pharmaceutically acceptable salt or an *in vivo*
30 hydrolysable ester thereof.

7. A compound of formula (I) as depicted in claim 1 wherein:

p is 0;

R² is hydrogen, 2-ethoxyethyl, 2-methoxyethyl, 2-hydroxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl;

R³ is hydrogen;

R⁴ is methyl, ethyl, propyl, isopropyl or 1-methoxyprop-2-yl; or

R⁵ is methoxymethyl, 2-methoxyethyl, 2-hydroxy-2-methylpropyl, propyl, isopropyl, ethyl, butyl, isobutyl, cyclopropyl, 2-methyl-1-propenyl, 3-butenyl, 1-propenyl, 3,3-

10 dimethylbutyl, phenethyl, dimethylaminomethyl, ethylaminomethyl, ethoxymethyl,

methylthiomethyl, isopropylthiomethyl, ethylthiomethyl, ethylsulphinlmethyl,

ethylsulphonylmethyl or isopropoxymethyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

15 provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[*N*-(2-

methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-

20 imidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-

(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(*N*-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(*N*-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-

methoxyethyl)sulphamoyl]anilino}pyrimidine.

25

8. A compound of formula (I) as depicted in claim 1 selected from:

4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;

4-(1-isopropyl-2-methoxymethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;

30 4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino}pyrimidine;


4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(allyl)sulphamoyl]anilino}pyrimidine;

4-(1-isopropyl-2-cyclopropylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;

4-(1-methyl-2-propylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;
 4-(1-ethyl-2-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
 4-(1-isopropyl-2-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
 pyrimidine;
 5 4-(1-isopropyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}
 pyrimidine; and
 4-(1-isopropyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine;
 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

- 10 9. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein R^1 , R^2 , R^3 , R^4 , R^5 and p are, unless otherwise specified, as defined in claim 1) comprises of:


Process a) reaction of a pyrimidine of formula (II):



(II)


15

wherein L is a displaceable group; with an aniline of formula (III):



(III)


Process b) reacting a compound of formula (IV):



(IV)

20


with a compound of formula (V):



(V)


wherein T is O or S; R^x may be the same or different and is C₁₋₆alkyl;

Process c) reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with an amine of formula (VII):



(VII)


10 or

Process d) reacting a pyrimidine of formula (VIII)



(VIII)

with a compound of formula (IX):



where Y is a displaceable group;

and thereafter if necessary:

- 5 i) converting a compound of the formula (I) into another compound of the formula (I);
 - ii) removing any protecting groups;
 - iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.
10. A pharmaceutical composition which comprises a compound of the formula (I), or a
- 10 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in association with a pharmaceutically-acceptable diluent or carrier.
11. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo*
- 15 hydrolysable ester thereof, according to any one of claims 1-8, for use in a method of treatment of the human or animal body by therapy.
12. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo*
- hydrolysable ester thereof, according to any one of claims 1-8, for use as a medicament.
- 20 13. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.

14. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in the manufacture of a medicament for use in the treatment of cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
15. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, in the manufacture of a medicament for use in the treatment of cancer.
16. The use according to claim 15 wherein the cancer is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.
17. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.
18. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, for use in the treatment of cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
19. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, for use in the treatment of cancer.

20. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-8, for use in the treatment of leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and
5 cancer of the vulva.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB/00935

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D403/04 C07D405/14 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 20512 A (BREault GLORIA ANNE ; THOMAS ANDREW PETER (GB); ASTRAZENECA UK LTD) 14 March 2002 (2002-03-14) the whole document	1-20
Y	WO 02 04429 A (THOMAS ANDREW PETER ; ASTRAZENECA UK LTD (GB); HEATON DAVID WILLIAM) 17 January 2002 (2002-01-17) cited in the application the whole document	1-20
Y	WO 01 14375 A (BEATTIE JOHN FRANKLIN ; BREault GLORIA ANNE (GB); JEWSBURY PHILLIP) 1 March 2001 (2001-03-01) the whole document	1-20
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

5 May 2003

Date of mailing of the international search report

12/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB/00935

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 53595 A (BREault GLORIA ANNE ; JAMES STEWART RUSSELL (GB); PEASE JANE ELIZAB) 14 September 2000 (2000-09-14) the whole document ----	1-20
Y	WO 01 64654 A (BREault GLORIA ANNE ; PEASE ELIZABETH JANET (GB); ASTRAZENECA UK LT) 7 September 2001 (2001-09-07) the whole document ----	1-20
A	WO 01 37835 A (ADAMS JERRY L ; JOHNSON NEIL W (US); MURRAY JEFFREY H (US); SMITHKL) 31 May 2001 (2001-05-31) the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB/00935

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0220512	A	14-03-2002	AU 8419201 A WO 0220512 A1	22-03-2002 14-03-2002
WO 0204429	A	17-01-2002	AU 6931701 A EP 1303496 A1 WO 0204429 A1 NO 20030146 A	21-01-2002 23-04-2003 17-01-2002 10-01-2003
WO 0114375	A	01-03-2001	AU 6583300 A BG 106383 A BR 0013476 A CA 2376293 A1 CN 1370163 T CZ 20020617 A3 EP 1214318 A1 WO 0114375 A1 HU 0202494 A2 JP 2003507478 T NO 20020832 A SK 2402002 A3	19-03-2001 30-09-2002 30-04-2002 01-03-2001 18-09-2002 12-06-2002 19-06-2002 01-03-2001 28-10-2002 25-02-2003 12-04-2002 10-09-2002
WO 0053595	A	14-09-2000	AU 754967 B2 AU 2818700 A BR 0008770 A CA 2366668 A1 CN 1349528 T EP 1161428 A1 WO 0053595 A1 JP 2002539120 T NO 20014317 A NZ 513893 A	28-11-2002 28-09-2000 08-01-2002 14-09-2000 15-05-2002 12-12-2001 14-09-2000 19-11-2002 01-11-2001 28-09-2001
WO 0164654	A	07-09-2001	AU 3395301 A CA 2399196 A1 CN 1406231 T EP 1272477 A1 WO 0164654 A1 NO 20024154 A	12-09-2001 07-09-2001 26-03-2003 08-01-2003 07-09-2001 28-10-2002
WO 0137835	A	31-05-2001	AU 1529901 A AU 1623601 A BR 0015532 A CA 2395564 A1 CZ 20021746 A3 EP 1232153 A2 EP 1233769 A1 WO 0138324 A2 NO 20022318 A TR 200201364 T2 WO 0137835 A1	04-06-2001 04-06-2001 25-06-2002 31-05-2001 16-10-2002 21-08-2002 28-08-2002 31-05-2001 15-05-2002 21-10-2002 31-05-2001